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The concentration of circulating blood calcium is vital to the function of many cellular 
processes. As such, it is maintained within a narrow range through the actions of gastrointestinal, 
bone, kidney, and endocrine tissues. In the kidney, the first portion of the nephron, called the 
proximal tubule (PT), performs the majority of solute reabsorption including about two-thirds 
of calcium. In vivo and ex vivo studies of PTs have shown that the major component of calcium 
reabsorption is passive and tightly linked to sodium reabsorption. This passive transport has long 
been suspected to be paracellular. The precise mechanisms and molecular facilitators of calcium 
reabsorption in the PT, however, remain unknown. Claudins are a group of transmembrane tight 
junction (TJ) proteins that are vital to the regulation of paracellular transport. In the PT, claudin-2 
is a highly expressed isoform. Claudin-2 increases the calcium permeability of renal epithelial 
cells upon overexpression. In addition, it was previously shown that mice with deletion of claudin-
2 have increased urinary calcium excretion. I hypothesized that PT calcium reabsorption is 
facilitated by claudin-2. My overall hypothesis was tested in several ways. 
First, I examined the patterns of claudin expression in the proximal nephron and found 
that claudins-2 and -10a are expressed throughout the PT, in both convoluted and straight 
segments. In contrast, claudin-3 is expressed only within the proximal straight tubule (PST). 
Furthermore, claudin-2 and claudin-3 expression are found in separate and distinct 
subpopulations of thin descending limbs. Next, I used co-immunoprecipitation experiments to 
show that claudin-2 physically interacts with claudin-3. Then I generated renal epithelial cell lines 
with inducible expression of PT claudins, claudin-2 and either claudin-3 or claudin-10a. I found no 
effect of claudin-3 overexpression on conductance or sodium permeability (PNa), with or without 
claudin-2 expression. However, overexpression of both claudins-2 and -10a led to a highly 
conductive cell monolayer with loss of charge selectivity. The results of calcium permeability 
assays show that calcium transport was reduced with co-expression of claudins-2 and -10a but 
unchanged with co-expression of claudins-2 and -3. In order to test the potential contribution of 
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claudin hetero-oligomerization on these permeability properties, I measured permeability of 
claudin-2/claudin-10a cells with titrated expression of each protein and with blockage of the 
claudin-2 pore. My results suggest that, rather than forming a hybrid channel with novel 
characteristics, claudin-2 and claudin-10a form pores in parallel.  
Next, I tested the hypothesis that deletion of the claudin-2 gene Cldn2 in mice causes 
nephrocalcinosis similar to human kidney stone disease using micro-computed tomography 
(micro-CT) and histological analyses. My findings indicate that this papillary pattern of 
nephrocalcinosis shares striking similarities to human kidney stone disease. I also examined the 
mechanism of hypercalciuria in these animals and found both a reduction in renal calcium 
reabsorption and a large increase in intestinal calcium absorption. Our colleagues subsequently 
identified multiple SNPs in the CLDN2 locus that associate with human kidney stone disease. 
Importantly, cis-acting expression quantitative trait loci (eQTL) analysis reveals that these same 
risk variants correlate with reduced claudin-2 mRNA expression in human tissues. 
My work suggests that proximal delivery of calcium to the loops of Henle is important in 
the pathogenesis of nephrocalcinosis and kidney stone formation. In addition, claudin-2 
expression is an important mediator of calcium transport that is associated with kidney stone 
disease in humans. These findings have led to a better understanding of renal physiology and 
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Chapter 1: Claudins and Kidney Stones 
 
I am investigating the role of claudin-2 in calcium transport in the PT and gastrointestinal 
tract, as well as its role in the development of nephrocalcinosis and kidney stone disease. Claudin-
2 increases calcium flux of cell monolayers in vitro (Yu, Cheng et al. 2009) while mice with deletion 
of claudin-2 develop hypercalciuria (Muto, Hata et al. 2010).  This work describes novel findings 
in the pathogenesis of nephrocalcinosis and suggests a role for claudin-2 in the formation of 
kidney stones in humans. 
This introductory chapter will first cover our current knowledge regarding the role of TJs in 
calcium transport and calcium homeostasis. I will provide an introduction to TJ biology and 
underscore the fundamental role of TJs in normal mammalian physiology and disease. In 
particular, I will discuss the role of claudins in physiology by exploring human diseases caused 
by loss-of-function mutations in claudin genes. Next, I will describe our current knowledge of 
paracellular transport within the PT of the kidney, with a particular focus on mechanisms of 
calcium transport. Following this, the clinical features of the two most common forms of kidney 
stone disease in humans will be summarized. This includes a discussion of the pathogenetic 
mechanisms for stone formation and the gaps that remain in our present understanding. Finally, 
I will discuss the evidence that reduced PT calcium transport is a common feature of kidney stone 
formers, and explore the potential role that claudin-2 plays in calcium transport in the PT. 
In chapter 2, I explore the role of PT claudins in the paracellular permeability of renal 
epithelial cells in vitro. We have generated a novel dual-claudin inducible model with which to 
investigate the effects of dual claudin expression on permeability of cell monolayers. My findings 
show that the most prominent claudins within the PT, claudins-2 and -10a, form cation and anion 
pores, respectively. I hypothesized that the permeabilities imparted by claudins-2 and -10a would 
be additive. However, co-expression of claudin-2 and claudin-10a reduced the permselectivity 
imparted by either claudin alone and led to a low resistance monolayer with approximately equal 
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permeabilities to both sodium (PNa) and chloride (PCl). Thus, I investigated a potential model of 
claudin interaction in which co-expression of PT claudins leads to a hybrid channel with novel 
permeability properties. Subsequent experiments support the conclusion that PT claudins 
influence the permselectivity as parallel ion channels, with claudin-2 and claudin-10a forming 
separate pores rather than a hybrid pore in the TJ. 
In chapter 3, I investigate the mechanisms of hypercalciuria and explore the 
nephrocalcinosis phenotype of animals with deletion of claudin-2 (Cldn2-/y mice). My findings 
show that claudin-2 loss results in both a decrease in renal calcium reabsorption and an increase 
in intestinal calcium absorption. These data suggest that Cldn2-/y mice exhibit many similarities to 
human kidney stone formers. First, I describe a form of calcium deposition within the medullary 
region of the kidney which resembles deposits in human kidney stone formers. My 
characterization suggests that these deposits form in the lumina of loops of Henle. These 
intraluminal deposits resemble deposits found in humans that are hypothesized to precede human 
kidney stone formation. Genomic analysis of a large database of stone formers and non-stone 
formers reveals that multiple common SNPs at the CLDN2 locus associate with kidney stone 
disease in a Japanese population. These SNPs are common worldwide and associate with the 
reduced tissue mRNA expression of claudin-2. Thus, I suggest that reduced claudin-2 expression 
in the kidney is a common risk factor for kidney stone disease in humans. 
1.1 Junctional complexes and TJs 
Junctional complexes are massive multi-protein structures found at the interface between 
adjacent cells that help to maintain the integrity of the epithelial cell barrier. In vertebrates, the 
junctional complex is organized into three major components: the zonula adherens (intermediary 
junction), the macula adherens (desmosome), and the zonula occludens (TJ, Figure 1-1A) 
(Farquhar and Palade 1963). Another category of structures often found within the junctional 
complex of epithelia is the communicating junction, an example being the gap junctions (Figure 
1-1A) that allow passage of small molecules from cell to cell through hexameric channels called 
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connexons (Alberts 2002). Junctional complex components are large enough to be recognized 
by transmission electron microscopy (TEM) and freeze-fracture microscopy (Alberts 2002). 
Intermediary junctions and desmosomes both function to anchor cells firmly to each other, and 
their composition is largely made up of proteins from the cadherin family (Alberts 2002). The TJ 
is the most apical structure of the junctional complex. Whereas intermediary junctions and 
desmosomes are found associated with an intercellular space, no such space is observed at TJs 
(Farquhar and Palade 1963). In addition, TJs are found continuously along the apical membrane 
of adjacent cells, as opposed to the often discontinuous pattern of the other junctional complex 
components (Farquhar and Palade 1963). Given this, it is not surprising that the TJs form a seal 
separating the apical and basolateral environment of epithelia. This can even be appreciated 
using TEM, where electron-dense proteins such as hemoglobin or zymogens within epithelial 
lumina are barred passage at the TJ (Farquhar and Palade 1963). 
 Farquhar and Palade described the structure of TJs across a wide range of epithelial 
tissues, and found that within the kidney, in particular, the morphology of TJs changes from one 
portion of the nephron to another (Farquhar and Palade 1963). For instance, the most leaky 
portion of the nephron, the PT, has a relatively shallow TJ (~0.03µm in depth) and wide 
intercellular spaces, whereas the TJs of the high transepithelial resistance (TER) distal tubule 
segments are deep (~0.3µm in depth) and intercellular spaces are narrow (Farquhar and Palade 
1963). 
A few decades ago, several key proteins were discovered in association with TJs. Zonula 
occludens-1 (ZO-1) was first identified as a large (220 kDa) peripheral membrane protein 
localized to the TJ of epithelial cells (Stevenson, Siliciano et al. 1986). The discovery of ZO-1 led 
to the isolation of membrane fractions of liver specific to the TJ, allowing the identification and 
cloning of another TJ protein: the transmembrane protein, occludin (65 kDa) (Furuse, Hirase et 
al. 1993). Subsequent work identified a functional role for ZO-1 as a scaffolding protein joining 
occludin with the actin cytoskeleton (Fanning, Jameson et al. 1998). 
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1.2 The claudin family of proteins 
In 1998, Furuse et al. sequenced peptides from a 22 kDa transmembrane protein found 
in TJ membrane fractions and identified and cloned two full-length cDNAs with predicted peptide 
sequence similarity (Furuse, Fujita et al. 1998). These cDNAs encoded for two distinct four-pass 
transmembrane proteins that localize to the TJ of epithelial cells in vitro but do not share sequence 
homology with occludin (Furuse, Fujita et al. 1998). Furuse named the two proteins claudin-1 and 
claudin-2 after the Latin word claudere, or “to close” (Furuse, Fujita et al. 1998). Genetic ablation 
of claudin-1 in mice caused severe dehydration and neonatal death but did not result in 
morphologic alterations to the TJ or mislocalization of occludin (Furuse, Hata et al. 2002). 
Interestingly, despite normal TJ ultrastructure, loss of claudin-1 in mice allowed diffusion of a 600 
Da tracer towards the skin surface, indicating that it plays a vital role in creating an impermeable 
barrier between cells (Furuse, Hata et al. 2002). While claudin-1 appears to be a barrier claudin 
and is expressed in most tissues (Furuse, Fujita et al. 1998), claudin-2 is expressed exclusively 
in tissues with leaky epithelia such as the intestinal crypts (Rahner, Mitic et al. 2001) and the PT 
(Enck, Berger et al. 2001). In vitro expression of claudin-2 decreases the TER (Furuse, Furuse et 
al. 2001) by increasing the paracellular cation permeability of an epithelial cell monolayer 
(Amasheh, Meiri et al. 2002, Yu, Cheng et al. 2009). The extracellular cation pore formed by 
claudin-2 is estimated to be approximately 6.5 Å (Yu, Cheng et al. 2009, Li, Zhuo et al. 2014). 
These two initially characterized claudins demonstrate the range of functions of claudins at the 
TJ; claudins may function either to bar the passage of small molecules such as ions and water or 
facilitate the diffusion of such molecules across an epithelial layer, akin to extracellular ion 
channels. 
Since the initial discovery of claudins-1 and -2, at least 24 additional members of the 
claudin family have been identified (Hou, Rajagopal et al. 2013).  All of these proteins consist of 
four-transmembrane domains, 2 extracellular loops, and cytoplasmic C- and N-terminal tails (Hou, 
Rajagopal et al. 2013) (Figure 1-1B). The first extracellular loop (ECL1) of each claudin contains 
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a GLWCC motif and amino residues that confer the paracellular ion selectivity of a given isoform 
(Hou, Rajagopal et al. 2013). In addition, all claudins contain a postsynaptic density 95/discs 
large/ZO-1 (PDZ) binding domain at the C-terminal tail (Figure 1-1B). This domain is crucial for 
interaction with peripheral membrane scaffolding proteins such as ZO-1 (Itoh, Furuse et al. 1999). 
The first crystal structure of a claudin was resolved for mouse claudin-15 in 2014 (Suzuki, 
Nishizawa et al. 2014). Homologous proteins with analogous ECL1 motifs and PDZ binding 
domains are found throughout the animal kingdom, including in sponges, which are believed to 
be the closest living relatives of the earliest branch of Metazoa (Leys and Riesgo 2012). Given 
this, it is easy to speculate that claudins were a vital ingredient in the fundamental evolutionary 
recipe for formation of a multicellular epithelial layer. 
1.3 Claudins in Mendelian disease 
The role of claudins in normal physiology can perhaps best be explored by the spectrum 
of human diseases caused by claudin mutations. 
1.3.1 Familial hypomagnesemia with hypercalciuria and nephrocalcinosis 
In 1999, the first disease-causing mutations within the claudin family were described for 
the claudin-16 gene (CLDN16, originally identified as Paracellin-1, or PCLN-1) (Simon, Lu et al. 
1999). These are loss of function CLDN16 mutations that cause the autosomal recessive disorder 
familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) (Weber, Schneider 
et al. 2001, Konrad, Hou et al. 2008). FHHNC is characterized by impaired renal reabsorption of 
magnesium and calcium, bilateral calcification within the kidneys (nephrocalcinosis), and rapidly 
progressing tubulointerstitial kidney disease leading to kidney failure in adolescence or young 
adulthood (Weber, Schneider et al. 2001). Claudin-16 is located within the thick ascending limb 
of the loops of Henle (TAL) in the human kidney (Kirk, Campbell et al. 2010), the site of defective 
calcium and magnesium reabsorption in FHHNC (Blanchard, Jeunemaitre et al. 2001). The role 
of claudin-16 in TAL calcium and magnesium transport is likely to be complex. First, 
overexpression of claudin-16 in MDCK C7 cells increases paracellular magnesium permeability 
6 
 
(but not calcium) (Gunzel, Amasheh et al. 2009) and isolated TAL from claudin-16 knockout mice 
have reduced permeability to magnesium and calcium (Will, Breiderhoff et al. 2010). This 
suggests that claudin-16 may act as a divalent cation pore and directly mediate paracellular 
reabsorption in the TAL. On the other hand, claudin-16 also seems to modulate basolateral 
chloride secretion through calcium activated chloride channels (Gunzel, Amasheh et al. 2009) 
and increase paracellular PNa (Hou, Paul et al. 2005), thereby increasing the positive lumen 
potential which drives magnesium and calcium reabsorption in the TAL (Hou, Shan et al. 2007).  
In 2006, mutations in the gene for claudin-19, CLDN19, were discovered in patients with 
ocular abnormalities and visual impairment in addition to all of the characteristic symptoms of 
FHHNC (Konrad, Schaller et al. 2006). Claudin-19 seems to act as a chloride barrier and 
physically interact with claudin-16 in vitro, thereby increasing the cation to anion selectivity ratio 
of the paracellular pathway (Hou, Renigunta et al. 2008). Interestingly, in transgenic mice with 
knockdown of either claudin-16 or -19, it has been observed that the localization of both claudins-
16 and -19 are lost from the TAL TJ (Hou, Renigunta et al. 2009). Indeed, several FHHNC 
mutations have been shown to interfere with the physical interaction of claudins-16 and -19 (Hou, 
Renigunta et al. 2008), highlighting the complexity of heterogeneous claudin expression in vivo. 
1.3.2 Autosomal Recessive Deafness DFNB29 
In 2001, mutations in CLDN14, the gene for claudin-14, were first described as the cause 
of a form of nonsyndromic recessive deafness (Wilcox, Burton et al. 2001). Overexpression of 
claudin-14 in MDCK II cells (a low resistance renal epithelial cell line) leads to an increase in TER 
and reduction in cation permeability, suggesting that it functions primarily as a cation barrier (Ben-
Yosef, Belyantseva et al. 2003). The Organ of Corti of the inner ear contains sensory hair cells 
that depend on a high concentration of potassium within the endolymph of the scala media for 
adequate depolarization (Wilcox, Burton et al. 2001). Claudin-14 is expressed at the apical portion 
of hair cells in the organ of Corti (Wilcox, Burton et al. 2001). Mirroring the human disorder, 
claudin-14 knockout mice are also deaf, and this has been determined to be primarily due to the 
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degeneration of the sensory hair cells (Ben-Yosef, Belyantseva et al. 2003). This disease serves 
as an example of the physiological importance of claudins in the formation of a paracellular barrier. 
Claudin-14 is also expressed in liver and kidney tissues (Ben-Yosef, Belyantseva et al. 2003), 
and genetic associations between CLDN14 and nephrolithiasis will be discussed in more detail in 
the sections below. 
1.3.3 Neonatal Sclerosing Cholangitis Associated With Ichthyosis 
Mutations resulting in a premature stop codon in claudin-1 (CLDN1) were identified in 
2004 as the cause of an autosomal recessive disorder, neonatal sclerosing cholangitis associated 
with ichthyosis (Hadj-Rabia, Baala et al. 2004). In humans, claudin-1 is expressed in both 
hepatocytes and chloangiocytes (Hadj-Rabia, Baala et al. 2004). The disease presents in infants 
with jaundice and pale stools, similar to symptoms caused by obstruction of the bile duct, and 
ultimately leads to biliary cirrhosis and liver failure (Hadj-Rabia, Baala et al. 2004). The disorder 
is suspected to arise as a result of increased permeability of bile across these cells and 
subsequent bile duct injury (Hadj-Rabia, Baala et al. 2004). Loss of claudin-1 in mice leads to 
severe dehydration and a loss of barrier function in skin (Furuse, Hata et al. 2002), perhaps 
mirroring the symptom of ichthyosis in humans but with heightened severity (Furuse, Hata et al. 
2002). Likewise, early neonatal death in these mice may explain why liver disease and biliary 
obstruction were not identified (Furuse, Hata et al. 2002). These findings illuminate a central role 
for claudin-1 in the formation of epithelial barriers in various tissues. 
1.3.4 HELIX Syndrome 
Recently, a number of mutations have been described in the gene for claudin-10 
(CLDN10) which cause a complex multisystem syndrome that includes hypokalemic metabolic 
alkalosis, salt wasting, and increased renal magnesium and calcium reabsorption (Bongers, 
Shelton et al. 2017, Klar, Piontek et al. 2017, Hadj-Rabia, Brideau et al. 2018). CLDN10 
transcripts are alternatively spliced into separate isoforms that differ in their localization and 
permeability properties (Gunzel, Stuiver et al. 2009). Claudin-10a is a variant expressed only in 
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kidney and uterus. Claudin-10a localizes to the TJ and imparts chloride selectivity when 
overexpressed in MDCK II cells (Van Itallie, Rogan et al. 2006, Gunzel, Stuiver et al. 2009). In 
contrast, claudin-10b is a cation-selective isoform that is found throughout the body, including in 
the distal nephron (Gunzel, Stuiver et al. 2009) and the glandular tissue such as sweat glands 
(Klar, Piontek et al. 2017) and salivary glands (Hadj-Rabia, Brideau et al. 2018). Interestingly, one 
of the reports of CLDN10 mutations described two missense mutations specific only to isoform 
claudin-10b, leading to a syndrome of hypohidrosis, electrolyte imbalance, lacrimal gland 
dysfunction, ichthyosis, and xerostomia and thus termed HELIX syndrome (Hadj-Rabia, Brideau 
et al. 2018). There are subtle differences in the reported cases of CLDN10 mutations and disease 
but taken together these studies suggest that the major manifestations of the described 
tubulopathy are the result of defective claudin-10b function. 
1.4 Claudins within the PT of the kidney  
Similar to the patterns in TJ morphology, the expression pattern of claudins in the kidney 
is highly heterogeneous from one segment to another (Kirk, Campbell et al. 2010, Lee, Chou et 
al. 2015). Among many important functions, the kidneys remove waste products from blood and 
maintain ion homeostasis via regulation of blood pressure and the electrolyte composition of 
extracellular fluid (Hall and Guyton 2011). Each human kidney is composed of roughly one million 
individual units called nephrons. Each nephron is composed of a modified capillary bed that 
serves as a filtration unit (glomerulus) followed by a series of tubule segments with distinct 
functional properties. These properties allow the kidneys to filter waste products out of blood at 
an incredible rate (around 180L of plasma is filtered per day in a healthy human adult) while 
reabsorbing >99% of solutes and water (Hall and Guyton 2011). 
The PT is responsible for the reabsorption of approximately two thirds of sodium, chloride, 
water, and calcium by the kidney (Hall and Guyton 2011). A significant proportion of PT 
reabsorption of these ions is passive, following the electrochemical gradients set up by sodium-
coupled cotransport of nutrient osmolytes such as glucose and amino acids (Figure 1-2A) (Green 
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and Giebisch 1989). Active sodium-coupled cotransport is coupled with bicarbonate reabsorption, 
which leads to generation of a chloride gradient in the mid-PT (Figure 1-2C) (Liu and Cogan 
1984). Since the paracellular pathway is highly permeable to chloride, chloride is passively 
reabsorbed (Green and Giebisch 1989) and a positive lumen potential is generated. This small 
lumen potential, paired with an incredibly low TER, is believed to drive the paracellular 
reabsorption of sodium and calcium (Figure 1-2B-C) (Barratt, Rector et al. 1974). Figure 1-2 
depicts transport along the PT in early and mid-late portions of the segment. Claudin-2, as 
mentioned above, is a cation-selective isoform with high expression within the PT and the first 
portion of the thin descending limb (Enck, Berger et al. 2001). Using a knockout mouse model, 
Muto et al. (2010) showed that loss of claudin-2 in vivo leads to a reduction in the PNa of isolated 
PTs (Muto, Hata et al. 2010). In addition, claudin-2 knockout mice excrete more sodium than wild 
type following administration of hypertonic sodium chloride, suggesting that claudin-2 mediates 
paracellular sodium reabsorption in the PT (Muto, Hata et al. 2010). Claudin-2 also has been 
demonstrated to function as a water pore (Rosenthal, Milatz et al. 2010) and likely accounts for a 
fraction of water reabsorption in the PT (Schnermann, Huang et al. 2013). 
Considering that the kidneys reabsorb well over 100L of fluid and solutes per day, the 
chemical energy needed to drive transcellular transport of this quantity would seem to make 
glomerular filtration an evolutionarily precarious strategy for waste excretion. Previous work in our 
lab showed that loss of claudin-2 greatly increases renal energy consumption and predisposes 
kidneys to acute ischemic injury (Pei, Solis et al. 2016). This, we argue, is due to the ability of 
claudin-2 to allow passive transport of sodium in the PT, which otherwise must be reabsorbed 
through active, energy-consuming transcellular processes. As a result, claudin-2 allows PT 
reabsorption to be much more energy efficient (Pei, Solis et al. 2016). In a teleological sense, 
such a heavy reliance on passive wholesale ion transport is acceptable in the PT because much 




In addition to claudin-2, claudin-10 is also expressed within the PT (Kirk, Campbell et al. 
2010, Lee, Chou et al. 2015). As mentioned in Section 1-3-4, the CLDN10 gene is transcribed as 
multiple splice variants. The two major variants differ in their ECL1 loops and charge selectivity 
(Van Itallie, Rogan et al. 2006). In the PT of mice, the anion-selective variant claudin-10a is 
expressed (Gunzel, Stuiver et al. 2009). Thus, it is possible that claudin-10a provides the 
paracellular route for chloride reabsorption in the PT, although this has not been directly tested in 
animal models. In the distal portion of the PT, claudin-3 is highly expressed in the rat (Lee, Chou 
et al. 2015). Claudin-3 is believed to act primarily as a barrier claudin, and overexpression of 
claudin-3 in the highly cation-selective MDCK II cells reduces the cation permeability and 
increases TER (Milatz, Krug et al. 2010). Characterization of claudin expression in the human 
kidney has thus far focused on cortical sections only (Kirk, Campbell et al. 2010), and so the 
expression pattern of claudin-3 within the PSTs of homo sapiens is unknown. 
1.5 Nephrolithiasis in man 
Kidney stone disease, or nephrolithiasis, was common enough to be written about in 
ancient Mesopotamian medical texts, and a stone was even discovered in the bladder of a 5000 
year-old mummy (Tefekli and Cezayirli 2013)! Hippocrates’ Oath of Medical Ethics, a document 
written in the B.C. epoch and still taken by physicians today, states “I will not cut for stone, but 
will leave this to be done by practitioners of this work.” Indeed, kidney stones were operated on 
thousands of years ago with decidedly less evidence-based approaches than today such as 
urethral lavage of “medicated” milk, or, failing that, perineal lithotomy (in the age before antibiotics 
or anesthesia, an operation with considerable mortality) (Tefekli and Cezayirli 2013). Today, great 
strides have been made but many obstacles remain in the prevention and treatment of kidney 
stones. 
1.5.1 Prevalence and Clinical Manifestations of Stone Disease 
Nephrolithiasis continues to present a massive public health concern, afflicting an 
estimated 1 in 11 people in the United States (Scales, Smith et al. 2012). This number has 
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skyrocketed from about 1 in 26 people in 1974 (Stamatelou, Francis et al. 2003), and there is a 
strong association between nephrolithiasis and obesity and diabetes in the U.S. (Scales, Smith 
et al. 2012).  With this in mind, environmental factors such as diet and lifestyle seem to be playing 
an increasing role in the pathogenesis of the disorder. Unfortunately, most patients who 
experience a kidney stone will experience another, as it has a relapse rate of 75% within a 20 
year period (Moe 2006). 
Nephrolithiasis is considerably more common in males, affecting approximately 10.6% of 
males, compared with 7.1% of women (Scales, Smith et al. 2012). It is of note that at least some 
component of the disparity between sexes is related to polygenic inheritance (Resnick, Pridgen 
et al. 1968). Stone disease is more common in white, non-Hispanic people than black or Hispanic 
populations in the U.S. (Scales, Smith et al. 2012). 
Rather than being a diagnosis in and of itself, nephrolithiasis is often a manifestation of an 
underlying cause, and evidence is lacking to show that kidney stones can cause symptoms in the 
absence of an obstruction (Moe 2006). Thus, the clinical symptoms of kidney stones are related 
to the disorder causing the stone to form and ureteral obstruction by the stone itself. Obstruction 
classically causes symptoms of renal colic, a highly characteristic onset of pain as the stone 
passes from the renal pelvis through the ureter, occasionally accompanied by hematuria and, as 
the stone enters the lower urinary tract, dysuria (Moe 2006). The underlying cause of stone 
disease ultimately depends on the type of stones formed. For instance, the major risk factors for 
uric acid stones are a high concentration of urate and/or low pH of the urine, cystine stones are 
caused by a hereditary disorder causing the renal leak of basic amino acids, and magnesium 
ammonium phosphate stones are caused by an infection of the urinary tract by urea-splitting 
bacteria (Moe 2006). The most common stones are composed of calcium, accounting for over 
80% of stones. A host of risk factors are involved in calcium stone pathogenesis (Moe 2006). In 
1939, Flocks first described the association between calcium stones and high urinary calcium 
excretion, or hypercalciuria, which he was able to identify in 23 out of 35 patients with kidney 
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stones (Flocks 1939). While hypercalciuria may be caused by a monogenic disorder or systemic 
disease such as hypercalcemia, it is most often discovered in the absence of an identifiable cause 
and thus termed idiopathic hypercalciuria (Pak 1979). The risk factors for calcium stone formation 
will be discussed in more detail in the sections below. 
1.5.2 Basic Pathogenetic Mechanisms of Hypercalciuria 
In order for many vital processes in the body to function appropriately, serum calcium must 
be kept within a tight range. The body achieves this in large part via the action of the calcium-
sensing receptor (CASR) in various tissues along with the calciotropic hormones, parathyroid 
hormone (PTH) and the active form of vitamin D, 1,25(OH)2-vitamin D3. These in turn regulate 
intestinal absorption, bone resorption, and renal reabsorption of calcium (Hoenderop, Nilius et al. 
2005). Thus, it should come as no surprise that hypercalciuria can be due to increased intestinal 
absorption, increased bone resorption, or decreased renal reabsorption of calcium (Figure 1-3). 
Indeed, patients with idiopathic hypercalciuria are a heterogeneous group with characteristics of 
one or multiple of these abnormalities underlying the elevation in urine calcium (Pak 1979). 
Bone is the major site of calcium storage in the body, and, as such, a central tissue in the 
regulation of extracellular calcium (Hoenderop, Nilius et al. 2005). When serum calcium is low, 
reduced activity by CASR in the parathyroid glands leads to secretion of PTH (Hoenderop, Nilius 
et al. 2005). PTH acts on bone to stimulate bone resorption and thus increase serum calcium and 
phosphate concentrations (Taal, Brenner et al. 2012). Concurrently, PTH acts on the renal PT to 
reduce phosphate reabsorption and increase the activity of 25(OH)-vitamin D 1-α-hydroxylase, 
which converts the hormone vitamin D to its active form (Taal, Brenner et al. 2012). Additionally, 
PTH acts on the renal TAL and distal tubule to increase calcium reabsorption (Taal, Brenner et 
al. 2012). Hypercalciuria with bone resorption as a primary cause is termed ”resorptive 
hypercalciuria” and is usually due to hyperparathyroidism, prolonged immobilization, or osteolytic 
metastases; unlike idiopathic hypercalciuria, this type of hypercalciuria is typically accompanied 
by an increase in serum calcium (Pak, Kaplan et al. 1975, Stewart, Adler et al. 1982, Moe 2006). 
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Abnormally high bone resorption in the absence of hyperparathyroidism would be expected to be 
accompanied by fasting hypercalciuria and suppression of PTH and 1,25(OH)2-vitamin D3 
(Worcester and Coe 2008). 
In the case of increased intestinal calcium absorption, rising serum calcium leads to 1) 
increased filtered load of calcium in the kidney and 2) the suppression of PTH secretion and 
consequent reduction in renal calcium reabsorption (Pak 1979). In addition, urinary calcium 
excretion will decrease during fasting periods, although some patients experience a reduction but 
remain hypercalciuric (Heller, Zerwekh et al. 2007). Intestinal calcium absorption is mediated by 
both paracellular and transcellular processes (Bronner 1998). The majority of active calcium 
transport occurs in the duodenum, where it is regulated in part through the action of 1,25(OH)2-
vitamin D3 (Bronner 1998). Patients with intestinal hyperabsorption may have elevated or reduced 
1,25(OH)2-vitamin D3 levels, depending on whether hyperabsorption is a primary defect in the 
intestine or secondary (Pak 1979). Active calcium transport in the duodenum is transcellular, 
mediated by transporters that will be discussed in more detail in Chapter 3. Passive paracellular 
calcium reabsorption in the intestine is determined by the passive permeability of the tissue to 
calcium, the degree to which calcium is solubilized, and the transit time of calcium through the 
alimentary canal (Bronner 1998). 
In the kidney, a large number of potential mechanisms exist to affect renal calcium 
reabsorption, many of which will be discussed below in the context of known genetic factors 
influencing nephrolithiasis. It is estimated that approximately 70%  of calcium is reabsorbed in the 
PT, 20% in the TAL, and 8% in the distal convoluted tubule (DCT), with the remainder being 
excreted in the urine (Taal, Brenner et al. 2012). Figures 1-2, 1-5A, and 1-5B depict PT, TAL, and 
DCT mechanisms of calcium transport, respectively. As mentioned above, renal reabsorption is 
regulated by PTH and 1,25(OH)2 vitamin D3. Additionally, CASR is expressed in the TAL where it 
regulates the reabsorption of calcium and magnesium (Gong, Renigunta et al. 2012, Gong and 
Hou 2014). Regulation of renal calcium reabsorption will be discussed further in Chapter 3. 
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It is important to reiterate that bone, the gastrointestinal tract, and the kidney interplay 
heavily in the context of idiopathic hypercalciuria; for example, intestinal hyperabsorption reduces 
both renal calcium reabsorption and bone resorption, and vice versa in patients with a renal leak 
of calcium (Moe 2006). In addition, the existence of absorptive hypercalciuria with fasting 
hypercalciuria suggests that idiopathic hypercalciuria occurs along a spectrum, and, while the 
mechanisms are not well known, some patients appear to have defects in both intestinal calcium 
absorption and renal calcium reabsorption. 
1.5.3 Other Risk Factors in Calcium Nephrolithiasis 
In addition to hypercalciuria, a high concentration of urinary oxalate is a major risk factor 
in calcium nephrolithiasis by increasing the supersaturation of calcium oxalate (CaOx), the most 
common type of calcium stone (Moe 2006). Similarly, urine phosphate levels affect the saturation 
of calcium phosphate in the urine and contribute to stone risk. Urine pH is a major factor affecting 
calcium phosphate stone formation, specifically, as these types of calcium salts are much less 
soluble at a high urinary pH (Moe 2006). Citrate is an inhibitor of calcium phosphate stone 
formation largely due to its role in allowing excretion of base without raising urine pH, and so low 
urine citrate can contribute to calcium phosphate nephrolithiasis (Moe 2006). In addition, a high 
sodium diet increases urine calcium excretion and reduces citrate, thereby posing another risk 
factor in stone formation (Moe 2006). 
The common link between virtually all risk factors for kidney stone formation is the 
supersaturation of crystallizing solutes (Moe 2006). Given this, decreased urine volume is a risk 
factor underlying all forms of nephrolithiasis, including calcium nephrolithiasis (Moe 2006). Low 
urine volume increases the risk of stone due to 1) increased concentration of solutes during urine 
formation and 2) relative urinary stasis (Moe 2006). 
Besides these urinary abnormalities, which by and large affect the supersaturation of 
calcium crystals, a major factor in the pathogenesis of kidney stones is thought to be the 
deposition of calcium crystals within the kidney itself, a phenomenon known as nephrocalcinosis. 
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1.5.4 Stone composition and the role of nephrocalcinosis in stone formation 
Several types of nephrocalcinosis have been implicated to have a major role in 
nephrolithiasis. In 1937, Randall first observed and described hydroxyapatite (a calcium 
phosphate mineral) plaque formation as the initiating step in the pathogenesis of calcium stones, 
so called Randall’s plaques (Randall 1937). Randall’s theory has been validated and extended, 
including by key work showing that these plaques form on the basement membrane of thin limbs 
of the loops of Henle and provide the base for concomitant precipitation of calcium crystals (Evan, 
Lingeman et al. 2003). These plaques are located within the deepest part of the renal medulla, 
termed the papilla (Figure 1-4A and 1-4B). While humans have multiple papillae within each 
kidney, mice only have one solitary papilla (Figure 1-4C). Subsequent work by Evan, et al. (2006) 
revealed that Randall’s plaques are relatively specific to CaOx stone formers; plaques that are 
close to the papillary surface allow growth of CaOx stones on the wall within the renal calyces. 
Indeed, removal of attached papillary CaOx stones can reveal underlying plaques (Evan, 
Lingeman et al. 2006). A separate form of nephrocalcinosis is found in patients with stones 
composed of primarily hydroxyapatite. These patients commonly have large intratubular plugs of 
calcium phosphate within the terminal portions of the collecting ducts (termed Bellini’s ducts) 
(Evan, Lingeman et al. 2014). In addition to these intratubular plugs, these patients also have 
calcium phosphate aggregations within the papillary interstitium termed novel interstitial plaque 
structures (NIPS) (Evan, Lingeman et al. 2014). NIPS may form due to the local interstitial calcium 
concentrations, as they do not appear to originate from within tubules (Evan, Lingeman et al. 
2014). Similarities between NIPS and nephrocalcinosis described in several animal models may 
suggest a common pathogenetic mechanism (Evan, Lingeman et al. 2014).  Figures 1-4C and 1-
4D show the expected locations of Randall’s plaques and intratubular deposits associated with 
calcium phosphate stones, respectively, on deep papillary cross-sections of mouse kidney 
(location denoted by magenta “X”). 
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Several mouse models have been generated that exhibit papillary nephrocalcinosis, 
although no animal models currently exist which exactly mimic human stone disease (Wu 2015). 
Chapter 3 will go into more detail regarding the characteristics of these various mouse models of 
nephrocalcinosis. 
1.5.5 Genetics of Hypercalciuria and Calcium Nephrolithiasis 
The significant contribution of genetics to nephrolithiasis is well established. In a large 
study comparing the families of kidney stone formers with relatives of unaffected spouses, it was 
found that polygenic inheritance is a major factor in risk for kidney stones (Resnick, Pridgen et al. 
1968). Likewise, a male-male twin study showed a stronger concordance rate among 
monozygotic twins (Goldfarb, Fischer et al. 2005). While polygenic inheritance is a major factor, 
almost one sixth of patients with kidney stone disease may have an underlying monogenic cause 
(Halbritter, Baum et al. 2015). A number of common variants and rare genetic mutations 
contribute to stone risk without causing hypercalciuria. For instance, causes of renal tubular 
acidosis can lead to failure to acidify urine and thereby increase the risk of stone formation. In 
addition, genetic causes of hyperoxaluria or hyperphosphaturia will increase the risk for calcium 
stone formation (Sayer 2017). Finally, several kidney-stone associated SNPs have been identified 
in the genes for calcium stone inhibitors OPN (coding for osteopontin) (Gao, Yasui et al. 2007) 
and UMOD (coding for uromodulin or Tamm-Horsfall protein) (Gudbjartsson, Holm et al. 2010). 
Regarding intestinal absorption, one study found that nearly half of the patients with 
absorptive hypercalciuria have a family history of kidney stones (Pak 1979). Despite this, relatively 
few genetic factors have been identified as direct causes of intestinal calcium hyperabsorption. 
One such putative absorptive hypercalciuria gene is ADCY10, which codes for the soluble 
adenylate cyclase 10; ADCY10 is thought to be mutated in autosomal dominant forms of 
nephrolithiasis (Reed, Heller et al. 1999, Halbritter, Baum et al. 2015). In addition, gain-of-function 
mutations in the intestinal calcium transporter, transient receptor potential vanilloid type 6 channel 
(TRPV6), have been identified in absorptive hypercalciuric kidney stone formers (Suzuki, Pasch 
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et al. 2008). SNPs in VDR, the gene for the vitamin D receptor, are also associated with kidney 
stone disease, and VDR is expressed in both intestine and kidney (Zhang, Nie et al. 2013). 
Hypercalciuria and nephrocalcinosis also occur in Mendelian intestinal diseases such as 
congenital sucrose/isomaltase deficiency (Belmont, Reid et al. 2002) and glucose/galactose 
malabsorption (Pahari, Milla et al. 2003), but these disorders occur in infancy and include 
hypercalcemia. 
Considerably more is known about the contribution of genetics to renal calcium 
reabsorption and nephrolithiasis. In the PT, a number of genetic factors have been identified. 
However, none of these seem to directly involve PT calcium transport mechanisms. For instance, 
a risk variant in close proximity to AQP1, the gene for aquaporin-1, implicates PT water transport 
in the development of nephrolithiasis (Urabe, Tanikawa et al. 2012). AQP1 knockout mice exhibit 
severe dehydration upon water restriction (Ma, Yang et al. 1998), and dehydration is a major risk 
factor in kidney stone disease. It is unknown if AQP1 variants in humans are associated with 
increased urine calcium excretion. Dent disease types I (CLCN5 gene) and II (OCRL gene) both 
involve the PT and include hypercalciuria, nephrocalcinosis, and nephrolithiasis in addition to a 
number of defects in PT reabsorption (low molecular weight proteinuria, aminoaciduria, 
glucosuria, and phosphaturia) (Hoopes, Shrimpton et al. 2005). Figure 1-2 depicts transport 
mechanisms believed to be involved in the passive transport of calcium in the PT. 
In the TAL, many defects are known to lead to nephrocalcinosis and nephrolithiasis. 
Bartter syndrome is a grouping of rare disorders of TAL sodium transport resulting in 
hypercalciuria and increased risk of kidney stones, as well as hypotension, hypokalemia, and 
metabolic alkalosis (Hebert 2003). Causative mutations in Bartter syndrome have so far been 
identified in five genes: loss-of-function mutations in SLC12A1 (coding for the Na+-K+-2Cl- 
cotransporter 2, or NKCC2), KCNJ1 (coding for the renal outer medullary potassium channel also 
known as ROMK or Kir1.1), CLCNKB (coding for the chloride channel Kb, or CLC-Kb), and BSND 
(coding for Barttin, a β-subunit of ClC-K channels required for correct trafficking of chloride 
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channels to the basolateral plasma membrane), as well as gain-of-function mutations in the CASR 
gene (Hebert 2003). In addition, patients with FHHNC have an increased risk of kidney stones in 
addition to hypercalciuria and nephrocalcinosis (Sayer 2017). Figure 1-5A depicts calcium 
transport mechanisms in the TAL. 
Finally, in the DCT calcium transport occurs across the apical membrane via the transient 
receptor potential cation channel V5 (TRPV5), and a rare coding variant has been identified in 
the TRPV5 gene that greatly increases kidney stone risk (Oddsson, Sulem et al. 2015). In addition 
to TRPV5, DCT calcium transport is believed to be facilitated by the cytoplasmic shuttle protein 
calbindin-D28k and transported out of the cell by several potential basolateral transport proteins 
(Hoenderop, Nilius et al. 2005). Figure 1-5B depicts the purported mechanisms of calcium 
transport in the DCT, which will be discussed in more detail in chapter 3. 
1.6 Overall Hypothesis of Dissertation: Claudin-2 mediates PT calcium transport 
My overall hypothesis is that claudin-2 mediates calcium reabsorption in the PT, and loss 
or reduction of claudin-2 increases nephrolithiasis risk. There is abundant evidence that PT 
reabsorption plays a major role in the pathogenesis of idiopathic hypercalciuria and calcium stone 
formation. Calcium stone formers respond abnormally to diuretic administration in a pattern 
suggestive of defective PT sodium reabsorption (Sutton and Walker 1980). This is particularly 
true for patients with fasting hypercalciuria (Sutton and Walker 1980, Sakhaee, Nicar et al. 1985).  
More recently, larger studies of idiopathic hypercalciuric stone formers have measured lithium 
clearance, a well-established surrogate of PT sodium reabsorption, and confirmed that decreased 
PT reabsorption is common among these patients (Worcester, Coe et al. 2008, Ko, Bergsland et 
al. 2015). Despite defective PT sodium reabsorption, these patients have normal fractional 
sodium excretion due to compensatory transport mechanisms in the downstream nephron 
(Worcester, Coe et al. 2008). Our lab and others have found similar defective PT sodium 
reabsorption in mice with deletion of claudin-2 (Muto, Hata et al. 2010, Pei, Solis et al. 2016). 
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Given that PT calcium transport is inextricably linked to PT sodium reabsorption 
(Alexander, Rievaj et al. 2014), the above findings suggest that defective PT calcium reabsorption 
is a common intrarenal cause of idiopathic hypercalciuria and thus calcium stone formation. 
Current evidence suggests that PT calcium reabsorption is primarily passive and likely to be 
paracellular (Figure 1-2B). Of the claudin isoforms highly expressed in the PT, only claudin-2 is 
cation-permeable. In addition, claudin-2 knockout mice have increased urine calcium excretion 
(Muto, Hata et al. 2010). In chapter 2, I explore my hypothesis by testing the electrophysiological 
and calcium permeability properties of PT claudin isoforms in combination, in vitro. In chapter 3, 
I use an in vivo mouse model with deletion of claudin-2 to test the hypothesis that 1) these animals 
are defective in PT calcium reabsorption and 2) they develop characteristics common to human 
kidney stone disease. Finally, I will consider the potential limitations, as well as future directions, 




Figure 1-1. The junctional complex and claudin family of proteins 
(A) The junctional complex helps to maintain the integrity of an epithelial cell barrier. Zonula 
occludens is the most apical component of the junctional complex and is composed in part by 
claudin proteins, followed by the zonula adherens and macula adherens. Gap junctions are also 
components of the junctional complex and allow direct communication between adjacent cells. 
(B) All members of the claudin family have 4 transmembrane domains, 2 extracellular loops (ECL1 
and ECL2), and cytoplasmic N- and C-termini. The first extracellular loop, ECL1, contains the 
residues that confer charge selectivity to pore-forming claudins. All claudins have a characteristic 
GLWCC motif on ECL1, as well. In addition, a PDZ binding domain is located in the C-terminal 






Figure 1-2. Proximal tubule paracellular transport 
(A) The early portion of the proximal tubule (PT) is the major site of sodium-coupled cotransport 
of solutes such as amino acids and glucose. This transport drives the paracellular transport of 
chloride. (B) In the mid-late PT, paracellular calcium transport is driven by small electrochemical 
gradients. (C) Transport of sodium is electrogenic in the early PT, thus generating a slightly 
negative lumen potential (~ -2mV). In addition, bicarbonate and water are reabsorbed secondary 
to the action of the sodium-hydrogen exchanger, increasing the intraluminal chloride 
concentration slightly above that of plasma. The chloride concentration gradient leads to 
paracellular chloride reabsorption, which generates a slightly positive lumen potential in the mid-
late PT (~ +2mV). This lumen potential then is believed to drive passive paracellular transport of 




Figure 1-3. General mechanisms of hypercalciuria 
Hypercalciuria may be caused by reduced renal reabsorption of calcium, increased bone 















Figure 1-4. Renal architecture and anatomical location of stone-associated 
nephrocalcinosis 
(A) Illustration of the structure of superficial and juxtamedullary nephrons in association with 
overall renal architecture. Superficial nephrons have relatively short loops of Henle, whereas 
juxtamedullary nephrons have loops of Henle which descend into the inner medulla and papillary 
regions of the kidney. (B) Section from a Cldn2-/y mouse stained for markers of PT and thin 
descending limb (tdL) of the loops of Henle (AQP1, green) and collecting duct (CD) principal cells 
(AQP2, red). Von Kossa calcium staining is pseudocolored white. Mouse kidneys contain a single 
papilla. (C) Calcium deposition is expected to occur at the basement membranes of the thin 
descending limbs if nephrocalcinosis resembles Randall’s plaques (magenta Xs). (D) Calcium 
deposition is expected to occur within the inner medullary collecting ducts if nephrocalcinosis 
resembles calcium phosphate stone formers (magenta Xs). PCT= proximal convoluted tubule; 
PST= proximal straight tubule; taL= thin ascending limb; TAL= thick ascending limb; DCT= distal 
convoluted tubule; CD= collecting duct; OSOM= outer stripe of the outer medulla; ISOM= inner 




Figure 1-5. Calcium transport in the thick ascending limb and distal convoluted tubule 
(A) In the thick ascending limb, a large lumen positive potential drives paracellular calcium 
transport. This potential is generated by the activity of the Na+-K+-2Cl- cotransporter (NKCC2), 
and subsequent efflux of apical K+ through the renal outer medullary potassium channel (ROMK) 
and basolateral Cl- through the chloride channel Kb (CLC-Kb). Paracellular mediators of calcium 
transport are claudins-16 and -19. Activation of the calcium-sensing receptor (CASR) leads to 
upregulation of claudin-14, which is a barrier claudin, thereby reducing paracellular calcium 
transport. (B) In the distal convoluted tubule, apical calcium is transported via the transient 
receptor potential cation channel subfamily V member 5 (TRPV5). Cytoplasmic calcium shuttle 
protein calbindinD-28k (CB-28k) is believed to facilitate intracellular calcium movement to the 
basolateral membrane, where it is extruded by plasma membrane calcium ATPase (PMCA1b) 
and the Na+-Ca2+ exchanger (NCX1). TRPV5, CB28k, and PMCA1b expression are regulated by 
1,25(OH)2-vitamin D3. Transport in both segments is regulated in part by parathyroid hormone 
(not shown) (Taal, Brenner et al. 2012). 
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Chapter 2: Co-expression of PT claudins leads to distinctive permeability properties 
 
2.1 Abstract 
The permeability of the paracellular pathway is determined by the apical TJ, which forms 
a seal between epithelial cells and can either form a tight barrier or pores that allow permeation 
of small ions across the intercellular space. Claudins are TJ proteins that in part determine the 
paracellular permeability of epithelia. The PT is characterized by a highly conductive paracellular 
pathway, which is believed to contribute to a significant amount of solute and water reabsorption 
by the kidney. I sought to identify the expression pattern of the major claudins expressed in the 
PT and found that claudin-2 and claudin-10 are expressed throughout the PT, whereas claudin-3 
is strongly expressed within the late PST. Additionally, claudin-2 and claudin-3 are expressed 
exclusively within the descending thin limbs of long loop and short loop nephrons, respectively. I 
next developed a novel dual-claudin induction cell model with which to characterize the net effect 
of PT claudin expression, in vitro. In keeping with previous studies, I found that claudin-2 
increases cation permeability in MDCK I cells while claudin-10a increases anion selectivity. 
However, claudin-3 expression had a negligible effect on all measures of our electrophysiological 
characterization, with or without claudin-2 expression. Co-expression of claudins-2 and -10a led 
to a high conductance monolayer with essentially unbiased ion selectivity. Utilizing the titrability 
of this cell system and a claudin-2 mutant in which the pore can be blocked with thiol-reactive 
reagents, I explored this reduction in permselectivity further and determined that claudins-2 and -
10a form paracellular channels in parallel, rather than participating in heteromeric hybrid channel 
formation. 
2.2 Introduction 
The PT is a ‘leaky’ epithelium with low TER and high conductance of both sodium and 
chloride through the paracellular shunt pathway (Rector 1983). This segment is responsible for 
the reabsorption of approximately 60% of sodium and chloride filtered by the glomerulus (Suki 
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1979, Berry and Rector 1991). Small electrochemical gradients are established early in the PT, 
largely via energy-consuming sodium-coupled cotransport of nutrient osmolytes such as glucose 
and amino acids and the selective transcellular reabsorption of sodium and bicarbonate (Rector 
1983).  The paracellular shunt pathway is more permeable to chloride than bicarbonate, 
facilitating paracellular chloride reabsorption as the luminal chloride concentration increases 
relative to plasma (Rector 1983, Berry and Rector 1991). Passive chloride reabsorption in turn 
generates a small lumen positive potential that drives passive reabsorption of cations (Berry and 
Rector 1991). Additionally, convective forces could potentially contribute to sodium, chloride, and 
calcium reabsorption due to the relatively low reflection coefficient for these ions compared with 
that of reabsorbed bicarbonate, sugars, and amino acids (Berry and Rector 1991). 
Claudins were first discovered in 1998 by Furuse et al. as four-pass transmembrane 
proteins within TJ subcellular fractions (Furuse, Fujita et al. 1998). There are ≥ 24 different 
isoforms of claudins, some of which reduce the conductance of an epithelial layer, while other 
isoforms increase transepithelial conductance with charge specificity, acting as paracellular pores 
(Hou, Rajagopal et al. 2013). Most tissues express multiple claudin isoforms in a cell-type specific 
pattern, including the kidney (Kiuchi-Saishin, Gotoh et al. 2002). Claudin proteins have been 
demonstrated to interact within the same cell (cis) and across adjacent cells (trans) (Furuse, 
Sasaki et al. 1999). The importance of claudin interactions are underlined by the inability of 
claudin-16 to traffic to the TJ in the absence of claudin-19, in vivo, (Hou, Renigunta et al. 2009) 
and of claudin-4 to traffic to the TJ of renal epithelial cells following knockdown of claudin-8 (Hou, 
Renigunta et al. 2010). The most consistent data across species indicate that the major claudins 
expressed in the PT are claudin-2, claudin-3, and claudin-10 (Gunzel, Stuiver et al. 2009, Kirk, 
Campbell et al. 2010, Lee, Chou et al. 2015). 
Claudin-2 has been shown to be expressed in the PT and thin descending limb of the 
kidney (Enck, Berger et al. 2001, Kiuchi-Saishin, Gotoh et al. 2002). In vitro claudin-2 
overexpression MDCK I with high TER decreases the TER primarily by increasing paracellular 
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cation permeability (Furuse, Furuse et al. 2001, Amasheh, Meiri et al. 2002, Yu, Cheng et al. 
2009). Interestingly, the related cell line, MDCK II, has high endogenous claudin-2 expression 
and low TER; genetic deletion of claudin-2 in MDCK II results in a striking increase in TER and 
decrease in cation permeability (Tokuda and Furuse 2015). In vivo, knockout of claudin-2 results 
in a reduction in the PNa of isolated PTs (Muto, Hata et al. 2010). In addition to increasing cation 
permeability, claudin-2 also functions as a paracellular water channel, facilitated through the same 
extracellular pore residues that confer cation selectivity (Rosenthal, Milatz et al. 2010, Rosenthal, 
Gunzel et al. 2017). 
In the mouse kidney, claudin-3 was first described in the thin ascending limb and TAL of 
the loops of Henle and more distal segments of the nephron (Kiuchi-Saishin, Gotoh et al. 2002). 
More recently, deep sequencing of microdissected rat kidney tubule segments suggests that 
claudin-3 is also highly expressed within the final segment of the PT (S3) and the short 
descending thin limbs (Lee, Chou et al. 2015). Immunohistochemical analyses of human cortical 
kidney sections has confirmed the expression of claudin-3 within the distal tubules, as well as 
weak basolateral staining within PTs; this study did not analyze claudin expression within the 
medullary regions of human kidney (Kirk, Campbell et al. 2010). Overexpression of claudin-3 in 
MDCK II cells was previously shown to lead to increased TER and a reduction in cation 
permeability, suggesting that it functions as a barrier claudin at the TJ (Milatz, Krug et al. 2010). 
In the kidney, claudin-10 is expressed as multiple transcripts via alternative splicing (Van 
Itallie, Rogan et al. 2006, Gunzel, Stuiver et al. 2009). These alternative splicing events result in 
two major isoforms of claudin-10, claudins-10a and -10b, which differ in the amino acid sequence 
of the N-terminal cytoplasmic tail, first transmembrane domain, and most of ECL1 (Van Itallie, 
Rogan et al. 2006). As ECL1 contains the amino acid determinants for charge selectivity in pore-
forming claudins (Colegio, Van Itallie et al. 2002), the functional difference between these 
spliceoforms was further explored. In vitro overexpression studies in MDCK II cells and LLC-PK1 
porcine kidney cells showed that claudin-10a increases anion selectivity, whereas claudin-10b 
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increases cation selectivity (Van Itallie, Rogan et al. 2006). In situ hybridization found that claudin-
10a is expressed primarily in the kidney cortex (Van Itallie, Rogan et al. 2006), and subsequent 
RT-PCR of microdissected tubule segments showed that this isoform is expressed more 
specifically in proximal convoluted tubule (PCT) and cortical collecting duct (CCD) (Gunzel, 
Stuiver et al. 2009). Claudin-10a mRNA expression was also detected in the medullary TAL, 
accompanied by claudin-10b expression (Gunzel, Stuiver et al. 2009). 
To date, there has not been detailed analysis of the physiological effects of co-expression 
of the major claudins in the PT. Thus, I aimed to determine the expression pattern of these three 
claudins in mouse tissue and analyze the effect of co-expression of these claudins, in vitro, using 
a novel dual induction overexpression model in high resistance MDCK I cells. 
2.3 Methods 
2.3.1 Tissue immunohistochemistry 
Animal experiments were carried out in accordance with NIH guidelines on the use of 
laboratory animals and were approved by the IACUC of the University of Kansas Medical Center. 
Animal tissues were fixed by intracardiac perfusion of 4% paraformaldehyde (PFA) and kidneys 
were either (A) cryoprotected overnight with 30% sucrose in PBS, embedded in Tissue-Tek OCT, 
and frozen or (B) fixed in 4% PFA overnight at 4ºC and embedded in paraffin. In either case, 5µm 
sections were prepared.  Sections were blocked in 1% bovine serum albumin and 5% normal goat 
serum in PBS prior to incubation with primary antibodies. Antibodies and dilutions were as follows: 
mouse anti-claudin-2 (Invitrogen, 1:500), rabbit anti-claudin-3 (Spring Biosciences, 1:500), rabbit 
claudin-10 (Invitrogen, 1:500), rabbit anti-UT-A2 (a generous gift from Dr. Jeff Sands, 1:500), and 
mouse anti-AQP1 (Abcam, 1:500). Slides were coverslipped with ProLong Gold Antifade 
Mountant with DAPI (ThermoFisher Sci.) and images captured with a Nikon80i upright 
microscope. Confocal images were captured with a Leica TCS SPE Confocal Microscope. 
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2.3.2 Co-immunoprecipitation experiments 
Sub-confluent HEK293 cells were transiently transfected (Lipofectamine 2000, 
ThermoFisher Sci.) with pcDNA3.1 claudin expression vectors and lysed in immunoprecipitation 
(i.p.) lysis buffer (50mM Tris-HCl, 150mM NaCl, 1% Triton-X100). Cells were mechanically 
homogenized with a syringe and 23G needle 7-10 times and centrifuged to sediment insoluble 
material (16,000G x 15min.). Cell lysates, pre-cleared with Protein G-Sepharose, were incubated 
with primary antibody overnight at 4ºC followed by Protein G-Sepharose beads. 
Immunoprecipitated beads were washed (50mM Tris-HCl, 150mM NaCl) and denatured by 
heating at 95ºC for 10 min prior to SDS-PAGE. Antibodies used were as follows: mouse anti-
claudin-2 (Invitrogen, 1:500), rabbit anti-claudin-3 (Invitrogen, 1:500), and rabbit anti-claudin-10 
(Invitrogen, 1:250). 
2.3.3 Generation of double-claudin inducible cell lines 
Basal medium for culture of MDCK I cells was DMEM with 5% fetal bovine serum. 
Retrovirus containing Tet-responsive human claudin-2 or mouse claudin-2 S68C was produced 
in the viral packaging line, PT67, and transduced into the MDCK I TetOff cell line, as described 
previously (Angelow and Yu 2009). Stable clones were selected in hygromycin using cloning 
cylinders, and subsequently transfected (Lipofectamine 2000, ThermoFisher Sci.) with PiggyBac 
transposase and PiggyBac cumate switch-inducible vectors (System Biosciences) containing 
either human claudin-3 or human claudin-10a. Stable double-inducible clones were selected in 
puromycin using cloning cylinders. Doxycycline (20ng/ml) was omitted from the medium in order 
to induce claudin-2 expression. Unless otherwise specified, cumate was used at 3x concentration 
(90µg/ml) for induction of claudin expression. Expression and localization of selected clones was 
tested by immunoblotting and immunofluorescence, as described below. Human claudin-10a was 
amplified from human kidney cDNA, and the sequence was confirmed with 100% identity to the 




Cells were grown to confluence on tissue culture plates. Cells were washed and scraped 
into a lysis buffer containing 0.25M sucrose, 30mM histidine, and 1mM EDTA at pH 7 with 
protease inhibitors (cOmplete Mini, Roche Diagnostics). Mechanical lysis of confluent cells was 
achieved using a 25G needle, and lysates were centrifuged at 16,000G for 10min. at 4ºC. Lysates 
were heated at 95°C for 10min. in reducing SDS-PAGE buffer and loaded into a polyacrylamide 
gel. Protein was then transferred to a polyvinylidene difluoride (PVDF) membrane and blocked 
using 5% nonfat-dry milk. Primary antibody incubation was performed overnight at 4ºC using the 
following antibodies:  mouse anti-claudin-2 (Invitrogen, 1:500), rabbit anti-claudin-3 (Invitrogen, 
1:500), rabbit anti-claudin-10 (Invitrogen, 1:500), and rabbit anti-claudin-10 (Abcam, 1:500). 
Horseradish peroxidase conjugated secondary antibodies were incubated at a concentration of 
1:5000 (GE Healthcare Bio-Sciences) and bands detected using chemiluminesence (Pierce). 
2.3.5 Immunofluorescence 
Cells were grown to confluence on permeable polycarbonate membrane filters (Corning) 
under conditions described above for induction of claudin expression. Cells were fixed in methanol 
at -20ºC for 20 min. Membranes were blocked in 1% bovine serum albumin and 5% normal goat 
serum in PBS with 0.05% Triton-X100 prior to incubation with primary antibodies. Antibodies and 
dilutions were as follows: mouse anti-claudin-2 (Invitrogen, 1:500), rabbit anti-claudin-3 
(Invitrogen, 1:500), rabbit anti-claudin-10 (Invitrogen, 1:250), and rabbit anti-claudin-10 (Abcam, 
1:500). Fluorophore conjugated secondary antibodies from goat were added at a concentration 
of 1:1000 (Life Technologies). Slides were cover-slipped with ProLong Gold Antfade Mountant 
with DAPI (ThermoFisher Sci.) and images captured with a Nikon80i upright microscope. 
2.3.6 Electrophysiological characterization 
For initial characterization of clones, cells were plated at a confluent density (0.8 x 105 
cells/well) onto Snapwell filters (Corning). Initial experiments using claudin-2/10a inducible cell 
clones more monitored in a CellZScope (nanoAnalytics). On day 5, doxycyline and cumate were 
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added to designated wells. On Day 8-9, TER was stable in all induction conditions and cells were 
loaded into Ussing chambers for electrophysiological studies. Current-passing electrodes of Ag 
wire and voltage-sensing electrodes made of Ag/AgCl pellets were introduced to Ussing 
chambers via agar bridges prepared with 3M KCl and 3% agar. Ussing chambers were bubbled 
continuously with gas lifts and maintained at 37ºC throughout experiments.  Electrodes were 
connected through single channel input modules (DM-MC6) to a multichannel voltage/current 
clamp (VCC-MC6) controlled by a computer, with data acquired at 1s intervals using Acquire and 
Analyze software (Physiologic Instruments, San Diego, CA). Baseline TER for each condition is 
from averages of 24 data points, whereas the remainder of data is the average of 3 data points 
immediately before and after medium exchange. 
Standard Ringer’s solution contained 150mM NaCl, 10mM glucose, 2mM CaCl2, 1mM 
MgCl2, and 10mM Tris-HEPES at pH 7.4.  For NaCl dilution potential measurements, medium in 
the basolateral compartment was replaced by isosmotic Ringer’s solution with 75mM NaCl and 
150mM mannitol. For alkali metal bi-ionic potentials and organic cation diffusion potentials, the 
basolateral medium was switched to a Ringer’s solution with 150mM or 75mM, respectively, of 
the cation-chloride salt replacing NaCl. Liquid junction potentials were estimated with blank filters 
as described previously (Yu, Cheng et al. 2009). The Goldman-Hodgkin-Katz constant field 
voltage equation was used to calculate ion permeabilities, as described in detail by Yu (Yu 2011). 




where 𝑥 = 𝑒%(
+,
-.) 
V is the diffusion potential corrected for liquid junction potentials as described by Yu et al. (Yu, 
Cheng et al. 2009). β  is the ratio of permeabilities to sodium and chloride, PCl/PNa. At 37ºC, RT/F 
is 26.71mV. The ratio of activity, α, is 1.89 because the activity coefficients for NaCl at 150mM 
and 75mM are 0.752 and 0.797, respectively. 
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PNa and PCl were calculated and derived using the method of Kimizuka and Koketsu 








𝑃=> = 𝛽	 × 𝑃12 
The permeability ratio of a given cation, X+, relative to PNa (γ) was also calculated using 
the Goldman-Hodgkin-Katz equation and it was assumed that the activity coefficients of NaCl and 
XCl were identical, as described previously (Yu 2011). The equation for γ for exchange with 
150mM XCl was: 
γ = 	 (1 + 𝛽) × 𝑒@ 6A.C'D − 𝛽 
The equation for γ for exchange with 75mM XCl (α again is equal to 1.89) was: 
γ = 	1.89(1 + 𝛽) × 𝑒@ 6A.C'D − 1.89𝛽 − 1 
For experiments with the claudin-2 S68C mutant cell lines, 2-aminoethyl 
methanethiosulfonate (MTSEA) was prepared as a 100x stock solution (250mM) immediately 
prior to beginning each set of cells due to its extremely short half-life in aqueous solution. MTSEA 
was added to both apical and basolateral compartments of Ussing chambers and several minutes 
were allowed for blocking of the claudin-2 pore prior to NaCl dilution potential measurements. 
2.3.7 Calcium flux experiments 
Unidirectional calcium flux was measured in cells grown on Transwells (Corning) under 
conditions identical to those described for Ussing chamber experiments. Basal medium contained 
1.8mM CaCl2, and radiotracer (hot) medium was prepared by the addition of 45CaCl2 to obtain a 
specific activity of 2Ci/mol. Hot medium was added to the apical compartment of cells, and “cold” 
basal medium was added to the basolateral compartment. Samples of basolateral medium was 
taken at multiple time points. Background was subtracted from all CPM counts, and the counting 
efficiency of the liquid scintillation counter was determined by the calculated/expected counts in 
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a sample of 2Ci/mol hot medium. The amount of calcium transported per well was calculated as 
follows: 
𝐶𝑎6J	(𝑚𝑜𝑙) = 𝐶𝑃𝑀 ÷ 𝐶𝑜𝑢𝑛𝑡𝑖𝑛𝑔	𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦	 × X
𝑡𝑜𝑡𝑎𝑙	𝑏𝑎𝑠𝑎𝑙	𝑣𝑜𝑙𝑢𝑚𝑒
𝑠𝑎𝑚𝑝𝑙𝑒	𝑣𝑜𝑙𝑢𝑚𝑒







Calcium flux is expected to be linear, and thus flux was calculated as the slope of the best 
fit line of calcium transported at all time points, divided by the surface area. Calcium permeability 
can be calculated from this as the calcium flux divided by the calcium concentration, and 
expressed in units of 10-6 cm/s. 
2.4 Results 
2.4.1 Claudin-2 and claudin-10 are both expressed along the PT 
I analyzed kidney sections of adult mice by confocal microscopy and found that claudin-2 
and claudin-10 are co-expressed in PT segments (Figure 2-1A). The intensity of claudin-10 
staining appeared consistent throughout both PCTs and PSTs (not shown). In addition, intense 
basolateral staining of claudin-10 was found in nearby TAL segments (Figure 2-1A). All claudin 
antibodies used in these studies were generated against the C-terminal portion of the proteins, 
making it impossible to differentiate between claudin-10a and claudin-10b spliceoforms in the 
present study. 
2.4.2 Claudin-3 is expressed in the PST and short loop populations of thin descending 
limbs 
In mouse cortex, faint claudin-3 staining was occasionally detected within claudin-2-
positive PCTs (Figure 2-1B). In addition, strong claudin-3 expression was observed in the CCD 
(Figure 2-1B). At the corticomedullary boundary, where PCTs transition into PSTs, I observed 
strong claudin-3 expression that was continuous throughout the outer medulla (Figure 2-1C-D). 
The depth of claudin-2 positive basolateral invaginations is less within PSTs than the PCTs 
(Figure 2-1C), in keeping with morphologic analyses comparing the basolateral membranes of 
the differing segments of PT epithelia (Faarup, Holstein-Rathlou et al. 2011). 
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Interestingly, at the boundary of the outer and inner stripes of the outer medulla, where 
PSTs transition into thin descending limbs, I observed populations of thin limbs which exclusively 
expressed either claudin-2 or claudin-3 (Figure 2-1D). In order to determine whether these 
populations were specific to short or long loop segments, I immunostained kidney sections with 
aquaporin-1 (AQP1), a marker of thin descending limbs of long loop nephrons (Zhai, Fenton et 
al. 2007). Like claudin-2, I found that AQP1 stained a distinct population of thin limbs from claudin-
3 (Figure 2-2), suggesting that the claudin-3 positive tubules are not long loop descending thin 
limbs but rather short and/or intermediate descending thin limb segments (Kim, Lee et al. 2016). 
These thin limbs were dispersed throughout the inner stripe of the outer medulla. 
2.4.3 Claudin-3 overexpression does not alter the electrophysiological properties of 
MDCK I cells 
Co-immunoprecipitation experiments show that claudin-2 and claudin-3 interact, in vitro 
(Figure 2-3). I therefore generated a double-inducible cell line in which claudin-2 expression is 
repressed in the presence of doxycycline (Tet-Off) and claudin-3 expression is induced in the 
presence of cumate. While endogenous claudin-3 is generally high in MDCK I cells, I identified a 
stable clone with particularly low endogenous expression by Western blotting and confirmed TJ 
localization by immunofluorescence (Figure 2-4A-B). My results show no difference in TER upon 
overexpression of claudin-3 (Figure 2-4C). Similarly, I detected no change in the PNa, PNa/PCl, or 
unidirectional calcium flux upon overexpression of claudin-3 in MDCK I cells (Figure 2-4D-F). 
Moreover, induction of claudin-3 overexpression did not alter the permeability properties of 
claudin-2. 
2.4.4 Co-expression of claudins-2 and -10a reduces the permselectivity of MDCK I cells 
In an analogous set of experiments to those above, I generated claudin-2 Tet-Off cells 
with cumate-inducible claudin-10a expression and confirmed localization of claudin isoforms at 
the TJ (Figure 2-5A-B). Claudin-10a reduced TER to the same degree as claudin-2 (Figure 2-5C). 
Similar to findings from previous studies, claudin-10a increased PCl (p<0.0001) without affecting 
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PNa (Figure 2-5D), whereas claudin-2 increased PNa (p<0.0001, Figure 2-5D) without affecting PCl. 
However, I found a significant reduction in both the PNa and PCl in cells expressing both claudins 
compared with expression of claudin-2 or claudin-10a alone, respectively (Figure 2-5D-E). 
Interesting, the PNa/PCl of claudin-2/10a dual-expressing cells was not different compared with 
MDCK I cells without induction of claudin expression, indicating that the net effect of the 
combination of the two claudins was a lack of charge selectivity (Figure 2-5E). 
Upon measuring unidirectional calcium flux of this cell model, I found that claudin-10a 
reduced the permeability to calcium to a similar degree as sodium (Figure 2-5F). My major findings 
were confirmed in another clone (Figure 2-6). However, calcium flux did not differ between cells 
expressing claudin-2 and both claudins in this clone (Figure 2-6F). In a PT epithelial cell line, it 
has been shown that an osmotic gradient can increase unidirectional calcium flux (Pan, Borovac 
et al. 2012). Additionally, it has been demonstrated that claudin-2 permeates water as well as 
cations (Rosenthal, Milatz et al. 2010, Rosenthal, Gunzel et al. 2017), and osmotic water flux 
increases 22Na flux in high resistance MDCK cells (Rosenthal, Milatz et al. 2010). I hypothesized 
that conditions inducing water transport across the claudin-2 pore would also increase calcium 
flux via convective forces, or “solvent drag”. Thus, I induced water flux using a basolateral 
mannitol gradient, with and without osmotic compensation, and reduced water flux with an apical 
sodium gradient (Figure 2-7B). However, no effect of claudin-2 or claudin-10a was observed on 
the osmotic unidirectional flux of calcium (Figure 2-7A). 
2.4.5 Titratable expression of claudins in the dual induction system 
Co-expression of claudin-2 and claudin-10a led to reduced PNa and PCl compared with the 
permeability of the isoforms alone, respectively. I hypothesized that these claudins may form 
extracellular pores in 2 possible ways. First, pores may be formed in parallel along the TJ. In this 
parallel model, homomeric claudin-2 and claudin-10a channels are inserted into the TJ, and we 




𝑃12(aba2>) = 𝑃12(=>cd6) +	𝑃12(=>cd'e2) 
𝑃=>(aba2>) = 𝑃=>(=>cd6) +	𝑃=>(=>cd'e2) 
Assuming a linear relationship between the protein expression of each protein at the TJ 
and its permeability properties, then PNa or PCl should also have a linear relationship to induction 
of protein expression. 
𝑃12
𝑃=>D = f(𝑃12(=>cd6) + 𝑃12(=>cd'e2)) (𝑃=>(=>cd6) +	𝑃=>(=>cd'e2))
⁄ h 
 If we assume that the PNa of claudin-10a and the PCl of claudin-2 are very low, we can 




The second possibility is that these claudins form heteromeric extracellular pores (Figure 
2-8B). If claudins-2 and -10a form hybrid pores, the proportional expression of claudin isoforms 
would have a non-linear relationship with ion permeability. If the pore has novel permeability 
properties, then we might expect these properties to be most evident when the ratio of claudin-2: 
claudin-10a is 1:1. However, the results would be indistinguishable from the parallel model of pore 
formation if the properties of a claudin-2/-10a hybrid pore are intermediate between the properties 
to of either isoform alone. I sought to test this by using the titratability of our cell expression 
system. Our findings in two clonal cell populations suggest that expression of claudin-2 has a 
linear relationship with PNa regardless of the level of claudin-10a expression. Therefore, the two 
claudins are unlikely to form a pore with novel properties (Figure 2-9).  
Claudin-2 only contains two extracellular cysteine residues which together form a disulfide 
bond, thereby rendering them inaccessible to soluble thiol-reactive reagents such as MTSEA (Li, 
Angelow et al. 2013). As a result, cysteine-scanning mutagenesis, followed by covalent 
modification of cysteine residues with thiol reactive reagents, has proven useful for mapping the 
pore-lining residues of claudin-2 (Li, Zhuo et al. 2014). Of all of the putative pore-lining residues, 
mutagenesis of a serine residue in ECL1, claudin-2 S68C, resulted in a functional claudin-2 pore 
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with the greatest inhibition of conductance (>60%) following the addition of MTSEA (Li, Zhuo et 
al. 2014). In order to investigate the hypothesis that claudin-2 and claudin-10a form heterotypic 
extracellular channels, I utilized our double-inducible system with overexpression of this mutant, 
claudin-2 S68C, in addition to claudin-10a. If a hybrid pore with intermediate properties explains 
the reduced permselectivity of the dual induction condition, we would expect that blockage of 
claudin-2 would interfere with the pore and reduce PCl to a greater proportion than expected 
(based on the claudin-2 only induction condition). Similar to the wild type cell lines, I found that 
PNa and PCl are less than expected with dual induction. However, our findings showed that 
blockage of claudin-2 reduces PCl to a similar extent in claudin-2 and claudin-2/10a induction 
conditions (claudin-2/10a 0.20 vs claudin-2 0.24, Table 2-1). This suggests that claudin-2 and 
claudin-10a insert into the TJ via the parallel model (Figure 2-8A). 
2.5 Discussion 
The work presented here shows the expression pattern of the predominant claudin 
isoforms within the PT and thin descending limb of the loops of Henle. In addition, I generated a 
novel inducible dual-claudin expression model to study the effects of claudin co-expression in 
vitro. Specifically, I investigated the net effect of overexpression of claudin-2 with the other 
predominant claudin isoforms within the PT, claudin-10a and claudin-3.  
My present work showed that the expression of claudin-2 is strong throughout the PCT and PST, 
while claudin-10 was weakly expressed compared with expression in the TAL (Figure 2-1). It 
should be noted that our claudin-10 antibody is directed towards the C-terminus of the protein, 
which does not differ between claudin-10a and claudin-10b isoforms. Previously, microdissection 
experiments did not collect PST segments for detection of claudin-10a (Gunzel, Stuiver et al. 
2009), and, conversely, deep sequencing of microdissected PST segments did not distinguish 
between the two isoforms of claudin-10 (Lee, Chou et al. 2015). Thus, I am unable to distinguish 
between the isoforms myself, and I am working under the assumption that claudin-10a is also the 
dominant isoform within the PST. I am assuming this in part because in situ hybridization studies 
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grossly suggest that the claudin-10a isoform predominates in the cortex and outer stripe of the 
outer medulla, where PSTs are numerous (Van Itallie, Rogan et al. 2006). In contrast, claudin-
10b is relatively scarce in the outer stripe but highly concentrated in the inner stripe of the outer 
medulla, where TALs are abundant (Van Itallie, Rogan et al. 2006). 
In MDCK I cells, overexpressed claudin-2 and claudin-10a formed cation-selective and 
anion-selective pores, respectively, and co-expression reduced ion permselectivity to PNa and PCl 
(Figure 2-5). While heteromeric biochemical interactions between different claudin isoforms have 
been well described, there have been no studies that distinguished whether these interactions 
produced functionally heteromeric paracellular channels with novel functional properties. Here I 
used a novel double-inducible and titratable expression system to show that the claudin-2 and -
10a pores function independently and in parallel, as opposed to forming a heterotypic hybrid 
channel. 
As discussed in the introduction, the driving forces for passive sodium and water transport 
in the PT are small osmotic gradients and positive lumen potentials created secondary to passive 
chloride movement along its concentration gradient. These driving forces may result in a 
substantial amount of isosmotic fluid reabsorption along the PT due to the high permeability of 
the nephron segment, in vivo. An epithelium with high permeability to chloride, sodium, and water 
is key to large amounts of reabsorption occurring in this segment. I speculate that chloride 
movement occurs across the TJ mediated by claudin-10a, and claudin-2 provides the paracellular 
shunt pathway for sodium and water to follow. 
In contrast to claudin-2 and claudin-10a, claudin-3 was found only within the PSTs of the 
outer stripe of the outer medulla (Figure 2-1). According to micro-perfusion experiments in rabbits, 
PNa/PCl is higher in juxtamedullary PT segments compared with superficial segments (Kawamura, 
Imai et al. 1975, Jacobson and Kokko 1976, Warnock and Burg 1977, Berry, Warnock et al. 1978). 
In addition, studies in rabbits have shown that water permeability of the juxtamedullary straight 
PT segments is approximately double that of other PT segments (Van Der Goot and Corman 
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1991), and water permeability in the PST is in large part mediated by the paracellular pathway 
(Carpi-Medina and Whittembury 1988). While the contribution of claudins to paracellular 
permeability is well established, it is not clear how claudin-3 expression would contribute to the 
physiological properties observed in these experiments. It is established that cation and water 
permeation through claudin-2 are both mediated by the same pore lining residues (Rosenthal, 
Gunzel et al. 2017). Interestingly, overexpression of claudin-3 in MDCK II cells, which have high 
endogenous claudin-2 expression, did not alter water permeability despite a marked reduction in 
TER (Milatz, Krug et al. 2010). 
I discovered separate populations of thin descending limbs of Henle with claudin-2 or 
claudin-3 expression, and further identified the claudin-3 positive segments as thin descending 
limbs of a distinct population from those of long loop nephrons (Figure 2-2). This expression 
pattern of claudins may reflect the opposing permeability properties in long and short loop 
nephrons. The upper segments of descending thin limbs of long loop nephrons have a high PNa, 
which is likely related to the high expression of claudin-2 in these segments (Imai and Yoshitomi 
1990). In contrast, short descending limbs have much lower PNa, PCl (Imai and Yoshitomi 1990) 
and PNa/PCl (Imai 1984) than the upper descending thin limb segments of long loop nephrons. 
Short loop nephrons also have a high permeability to urea compared with long loop nephrons 
(Imai and Yoshitomi 1990). This high urea permeability is suggested to facilitate urea recycling 
from ascending vasa recta, which carry a large amount of urea from the inner medulla (Jamison 
1987). Urea recycling also occurs in the PSTs, with urea flowing from the cortical TALs of long 
loop nephrons (Jamison 1987). While it is unclear what claudin-3 contributes to urea recycling, it 
is interesting to note the high expression of claudin-3 in these segments. Our dual-claudin 
induction model may be utilized in future studies to investigate the effect of claudin-3 
overexpression on urea permeability. 
My findings indicate that overexpression of claudin-3 results in negligible effects on ion 
selectivity and TER, with or without the expression of claudin-2. This differs from previous findings 
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in MDCK II cells, mentioned above. As our model is based on the high TER cell line, MDCK I, and 
both human claudin isoforms are overexpressed in these cells, the results of the two studies are 
not necessarily interchangeable. A common concern of overexpression studies for studying 
claudin biology is the presence of endogenous claudins, which may affect the observed results 
(Gunzel and Yu 2013). Indeed, MDCK I cells have endogenous canine claudin-3 expression, and 
I attempted to mitigate these effects by carefully selecting a clonal cell line with low expression 
levels, by both immunoblotting and immunofluorescence (Figure 2-4). Future studies could utilize 
genomic editing techniques such as transcription activator-like effector nucleases (TALENs) in 
order to genetically knockout the endogenous claudin-3 gene in MDCK I cells, as was recently 
described by Tokuda (Tokuda and Furuse 2015). It will be interesting to explore the effects of 
these PT claudins further, especially given the strong co-expression of claudins-2, -3, and -10 
within juxtamedullary PSTs. 
The claudin-2 isoform was previously shown to increase unidirectional calcium flux in renal 
epithelial cells, but calcium flux had heretofore not been measured in overexpression studies of 
claudin-3 and claudin-10a. My findings suggest that only claudin-2 increases the cation and 
calcium permeability of MDCK I cells, while claudin-10a modulates permeability by reducing the 
paracellular permeability to cations. I have also shown that claudin-2 and claudin-10a form 
independent pores when inserted into the TJ rather than a hybrid pore. In cells inducible for 
claudin-3 and claudin-2, no difference was observed in calcium permeability or TER. While 
previous studies in low resistance cell lines have shown that claudin-3 increases TER (Milatz, 
Krug et al. 2010), my results suggest that this effect is counteracted by overexpression of claudin-
2. My major findings strengthen the evidence for claudin-2 as the putative paracellular calcium 




Table 2-1. Effect of claudin-2 pore blockage in cells with dual inducibility of claudin-2 
S68C and claudin-10a 
Ussing experiments in cells inducible for expression of claudin-2 S68C (cldn2) and claudin-10a 
(cldn10a). Unknown values or values less than zero are left blank 
PX(Cldn2-MTSEA) is the permeability of X that is attributable to cldn2 prior to blockage of pore with 
MTSEA 
*Expected values of cldn2/cldn10a dual induction conditions. PX values are sum of single claudin 





































































None 0.60 0.67   0.79 0.92   0.76 0.72 
Cldn2 6.54 2.59 3.95 0.60 1.73 1.34 0.39 0.24 3.91 2.04 
Cldn10a 0.63 0.64 
  
4.06 3.96 0.10 0.02 0.16 0.16 
Cldn2/10a 
expected* 
7.17 3.23 3.94 
 























Figure 2-2. Colocalization of PT claudins in adult mice 
(A) Tight junction colocalization of claudin-2 (cldn2) and claudin-10 (cldn10) in the kidney was 
detected throughout the proximal convoluted tubule (PCT). Strong basolateral claudin-10 staining 
was also detected in the thick ascending limb (TAL) and the straight proximal tubule segments of 
the outer medulla (not shown). (B-D) Colocalization of claudin-2 and claudin-3 in the PCT (B,C), 
proximal straight tubules (PST) (C,D), and thin descending limbs (tdl) (D). Claudin-2 and -3 
colocalize to both tight junction and basolateral membrane throughout the PST (C,D). At points 
where PSTs transition to tdls, some populations of tdl only express claudin-2, whereas others 
only express claudin-3 (D, arrowheads). Claudin-3 was also expressed in cortical collecting duct 







Figure 2-3. Localization of claudin-3 within short loop nephrons 
Claudin-3 (cldn3, red) expression is not found in long loop descending thin limb tubules, which 
express aquaporin-1 (aqp1, green).. Scale bars = 50µm. OSOM= outer stripe of the outer medulla; 





Figure 2-3. Co-immunoprecipitation of claudin-2 and claudin-3 
Human embryonic kidney cells (Hek293) were transiently transfected with claudin-2 (cldn2) and 
claudin-3 (cldn3), and sub-confluent cell lysates were collected. Input shows expression of both 
claudins in whole cell lysates. Cldn3 co-immunoprecipitated with cldn2, but neither was 




Figure 2-4. Claudin-3 expression has minimal effect on the electrophysiological 
properties of MDCK I cells 
MDCK I TetOff cells stably transfected with wild type human claudin-2 and claudin-3 under control 
of the tetracycline-controlled transactivator and cumate switch, respectively. Cells were grown in 
the presence (+) or absence (-) of doxycycline and cumate. (A) Representative immunoblots of 
clone with low endogenous claudin-3 expression used for electrophysiological characterization. 
(B) Immunolocalization of claudin-2 and claudin-3 in cells grown in the presence (+) or absence 
(-) of doxycycline and cumate. Scale bars = 25µm. (C) Cells were loaded into Ussing chambers 
for measurement of transepithelial resistance (TER) (n=6). (D) Permeability to sodium (PNa) was 
determined in dilution potential experiments. (E) Ratio of sodium and chloride permeability 
(PNa/PCl) (n=6). Data were log10 transformed prior to analysis. (F) Calcium (Ca2+) permeability was 
determined by unidirectional radiotracer flux assay (n=3). Data were analyzed by two-way 
ANOVA with Tukey’s correction for multiple comparisons and presented as Mean ± SEM. 
Significant differences compared with no claudin induction are represented by: *, P<0.05; **, 
P<0.01; ***, P<0.001; ****, P<0.0001. Significant differences compared with claudin-2 expression 




Figure 2-5. Co-expression of claudin-2 and claudin-10a leads to a reduction in 
permselectivity of MDCK I cell monolayers 
MDCK I TetOff cells stably transfected with wild type human claudin-2 and claudin-10a under 
control of the tetracycline-controlled transactivator and cumate switch, respectively. Cells were 
grown in the presence (+) or absence (-) of doxycycline and cumate. (A) Representative 
immunoblots of single clone (clone 9) used for subsequent electrophysiological characterization. 
(B) Immunolocalization of claudin-2 and claudin-10a in cells grown in the presence (+) or absence 
(-) of doxycycline and cumate. Scale bars = 25µm. (C) Cells were loaded into Ussing chambers 
for measurement of transepithelial resistance (TER) (n=9). (D) Permeability to sodium (PNa) was 
determined in dilution potential experiments. (E) Ratio of sodium and chloride permeability 
(PNa/PCl) (n=9). Data were log10 transformed prior to analysis. (F) Calcium (Ca2+) permeability was 
determined by unidirectional radiotracer flux assay (n=3). Data were analyzed by two-way 
ANOVA with Tukey’s correction for multiple comparisons and presented as Mean ± SEM. 
Significant differences compared with no claudin induction are represented by: *, P<0.05; **, 
P<0.01; ***, P<0.001; ****, P<0.0001. Significant differences compared with claudin-2 expression 




Figure 2-6. Results repeated in another clone co-expressing claudin-2 and claudin-10a 
MDCK I TetOff cells stably transfected with wild type human claudin-2 and claudin-10a under 
control of the tetracycline-controlled transactivator and cumate switch, respectively. Cells were 
grown in the presence (+) or absence (-) of doxycycline and cumate. (A) Representative 
immunoblots of single clone (clone 1) used for subsequent electrophysiological characterization. 
(B) Immunolocalization of claudin-2 and claudin-10a in cells grown in the presence (+) or absence 
(-) of doxycycline and cumate. Scale bars = 25µm. (C) Cells were loaded into Ussing chambers 
for measurement of transepithelial resistance (TER) (n=9). (D) Permeability to sodium (PNa) was 
determined in dilution potential experiments. (E) Ratio of sodium and chloride permeability 
(PNa/PCl) (n=9). Data were log10 transformed prior to analysis. (F) Calcium (Ca2+) permeability was 
determined by unidirectional radiotracer flux assay (n=3). Data were analyzed by two-way 
ANOVA with Tukey’s correction for multiple comparisons and presented as Mean ± SEM. 
Significant differences compared with no claudin induction are represented by: ****, P<0.0001. 








Figure 2-7. Claudin-2 mediated calcium flux is not increased by osmotic "solvent drag" 
Unidirectional radiotracer calcium flux experiments were performed on claudin-2/-10a dual 
induction cells (clone 9) under hyperosmotic conditions. (A) Results of calcium flux in 3 separate 
conditions revealed no significant effect of claudin-2 on calcium flux. No significant differences 
between control data were detected. Data were analyzed by two-way ANOVA with Tukey’s 
correction for multiple comparisons and individual values shown. Bars are Mean ± SEM (n=3). 
(B) Experimental conditions for the three gradient experiments are shown. Radiotracer calcium is 
added to apical chamber, as described in the methods. Mannitol was added to basolateral 




Figure 2-8. Two models of extracellular claudin pore formation with co-expression of PT 
claudins in MDCK I cells 
(A) In the parallel model of claudin pore formation, claudin-2 (cldn2) and claudin-10a (cldn10a) 
each insert in parallel into an otherwise poorly permeably tight junction strand. (B) An alternative 
model is that the combination of cldn2 and cldn10a expression leads to the formation of a hybrid 




Figure 2-9. Expression of claudins in relation to sodium permeability 
XYZ plot of PNa plotted against induction level of claudin-2 and claudin-10a. We induced varying 
levels of claudin-2 (doxycycline 0, 0.01, 0.1, and 20ng/µl) and claudin-10a (cumate 0, 30, 60, and 
90ng/µL) in our claudin-2/claudin-10a dual induction clones and performed dilution potential 
experiments. Clones show a direct relationship between claudin-2 expression and PNa regardless 





Chapter 3: Claudin-2 deletion causes nephrocalcinosis in mice and common CLDN2 
variants associate with human kidney stone disease 
 
3.1 Abstract 
Hypercalciuria and nephrocalcinosis are frequent findings in patients with recurrent kidney 
stone disease. Hypercalciuria is often idiopathic and related to unknown defects in intestinal or 
renal calcium transport. In the kidney, the majority of filtered calcium is reabsorbed in the PT by 
an unknown pathway. Claudin-2 is a calcium-permeable TJ protein highly expressed in the PT. I 
hypothesized that global deletion of the Cldn2 gene in mice would lead to defective renal calcium 
reabsorption and nephrocalcinosis. I first confirmed that Cldn2-/y mice exhibit increased urinary 
calcium excretion. Histological analyses revealed extensive intratubular calcium deposits in the 
loops of Henle of Cldn2-/y mice. Micro-CT analysis showed that deposits form between 4.5-6 
months of age, and micro-Fourier transform infrared spectroscopy (micro-FTIR) analysis 
determined the composition as primarily hydroxyapatite. Surprisingly, metabolic balance studies 
revealed that Cldn2-/y mice have a positive calcium balance compared with wild type animals. 
When placed on a calcium deficient diet, calcium excretion in Cldn2-/y mice was reduced to a 
much greater extent than in wild type mice but remained approximately double that of wild type 
mice on the calcium deficient diet. These results suggest that Cldn2-/y mice exhibit both intestinal 
hyperabsorption and defective renal reabsorption of calcium. Utilizing genotype association 
analysis including the X chromosome, our collaborators identified several SNPs in the CLDN2 
locus that associate with nephrolithiasis in the Japanese population. eQTL analysis revealed a 
strong correlation between risk variants and reduced claudin-2 mRNA expression. I conclude that 
claudin-2 is an important mediator of calcium transport in both kidney and the intestinal tract, and 
common CLDN2 variants are likely to contribute to the pathogenesis of kidney stone formation in 




Kidney stone disease is common, with a lifetime risk in the U.S. of about 10% (De, Liu et 
al. 2014). Health care expenditures for care related to nephrolithiasis is estimated to be more than 
$2 billion annually (Pearle, Calhoun et al. 2005). Studies of families (Resnick, Pridgen et al. 1968), 
twin concordance (Goldfarb, Fischer et al. 2005), and genome wide association (Thorleifsson, 
Holm et al. 2009, Gudbjartsson, Holm et al. 2010, Urabe, Tanikawa et al. 2012) have revealed a 
significant role for polygenic inheritance in the pathogenesis of the disease. The vast majority of 
stones are composed of calcium crystals, primarily calcium phosphate or CaOx (Walker, 
Stansbridge et al. 2013, Evan, Lingeman et al. 2014), and the major risk factor is an elevation in 
urine calcium, which is termed idiopathic hypercalciuria (Worcester and Coe 2010). Additional risk 
factors for kidney stone formation include low urine volume, hyperoxaluria, and hypocitraturia 
(Worcester and Coe 2010). The common causative factor in these metabolic abnormalities is 
supersaturation of calcium salts leading to precipitation and crystal growth (Worcester and Coe 
2010). 
 The pathogenesis of stone formation in patients with idiopathic hypercalciuria varies 
depending on the composition of the stone but the majority are believed to begin with deposition 
of calcium within the renal papilla, or papillary nephrocalcinosis (Evan, Lingeman et al. 2014). For 
patients with urinary stones composed of primarily CaOx, the precursor lesions are known as 
Randall’s plaques and are characterized by deposition of calcium phosphate within the interstitial 
space surrounding the basement membranes of the thin limbs of loops of Henle (Evan, Lingeman 
et al. 2003). By contrast, patients with predominately calcium phosphate urinary stones often have 
early intratubular calcium phosphate deposits in inner medullary collecting ducts, as well as 
interstitial aggregates of calcium phosphate termed NIPS that have microscopic features distinct 
from Randall’s plaques (Evan, Lingeman et al. 2014). All of these forms of intrarenal deposits are 
believed to eventually rupture through the papillary surface and thereby form a nidus for the 
growth of urinary stones. 
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 The etiology of idiopathic hypercalciuria is incompletely understood, but can generally be 
ascribed to increased bone resorption, intestinal hyperabsorption, and/or reduced renal 
reabsorption of calcium (Moe 2006). Studies of diuretic response and lithium clearance in patients 
with idiopathic hypercalciuria suggest that they have a specific defect in PT calcium reabsorption 
(Sutton and Walker 1980, Worcester, Coe et al. 2008). The PT reabsorbs approximately 60% of 
calcium filtered by the glomerulus (Suki 1979). It is highly permeable to calcium and the tubule 
fluid/plasma concentration ratio is about 1.1, suggesting that transport of calcium follows that of 
sodium and water (Suki 1979, Alpern, Hebert et al. 2008). In isolated perfused PTs, net calcium 
transport is zero in the absence of osmotic or potential differences, and reabsorption can be 
induced by applying a lumen positive potential difference (Ng, Rouse et al. 1984). This suggests 
that calcium reabsorption in the PT is passive and likely occurs by paracellular diffusion. 
Paracellular transport is mediated by a family of tetraspanning membrane proteins known 
as claudins that are found at the TJ between epithelial cells. These proteins act as charge-
selective channels or barriers regulating the movement of solutes across epithelial layers (Hou, 
Rajagopal et al. 2013). Claudin-2 is a cation-selective isoform (Furuse, Furuse et al. 2001, 
Amasheh, Meiri et al. 2002) that is permeable to both sodium and calcium (Amasheh, Meiri et al. 
2002, Yu, Cheng et al. 2009) and is highly expressed in the PT and the descending thin limb of 
the loop of Henle (Enck, Berger et al. 2001). Isolated PTs from claudin-2 knockout mice have 
increased TER and reduced PNa, and these animals exhibit a three-fold increase in the fractional 
excretion of calcium (FECa2+) (Muto, Hata et al. 2010), suggesting that claudin-2 mediates 
paracellular calcium reabsorption in the PT. 
In this study I tested the hypothesis that loss of claudin-2 predisposes mice to 
nephrocalcinosis and nephrolithiasis, mimicking the pathogenesis of human kidney stone 
disease. We explored the underlying mechanism and tested whether common polymorphisms in 




3.3.1 Animal studies 
The null allele of Cldn2tm1Lex/Mmcd mice was originally generated by targeted deletion of the 
coding exon of Cldn2 and backcrossed into the C57BL/6J background, as described previously 
(Pei, Solis et al. 2016). All studies used male mice due to the location of the Cldn2 gene on the 
X-chromosome, which precludes generation of wild type and knockout female littermates. 
Baseline measurements of urine and serum parameters were performed on 15-17 week-old mice 
fed standard lab chow (Teklad Rodent Diet 8604, Envigo). Urine was collected on Parafilm. Mice 
were then anesthetized with a xylazine (15 mg/kg i.p.) and ketamine (150 mg/kg) cocktail (1x) 
and blood was collected by cardiac exsanguination. To avoid possible interference of ketamine 
with PTH measurements, blood for this assay was collected from the submandibular vein of 
unanaesthetized 16 week-old mice into EDTA plasma tubes. 
3.3.2 qRT-PCR 
Tissue RNA was extracted with TRI Reagent (Sigma-Aldrich). First-strand cDNA iScript 
Reverse Transcription Supermix for RT-qPCR (Bio-Rad) was used for first-strand cDNA 
synthesis. qRT-PCR primers are listed in Table 3-1.  A CFX96 Touch Real-Time PCR Detection 
System and iTaq Universal SYBR Green Supermix (Bio-Rad) were used for quantitative PCR. 
Expression levels were normalized to housekeeping genes β-actin (kidney) or GAPDH (intestine). 
3.3.3 Immunoblotting 
Kidney tissue was homogenized by .009RD single edge blade (American Safety Razor 
Co.), and collected in protein isolation buffer composed of 20mM HEPES pH 7.4, 10mM KCl, 
2mM MgCl2, 1mM EDTA, and 1mM EGTA with protease inhibitors (cOmplete Mini, Roche 
Diagnostics). Each sample was homogenized for 15s increments every minute for 5 minutes at a 
low-speed setting with an Ultra-Turrax T25 (IKA-Labortechnik) and then centrifuged at 1800 x g 
for 10 minutes. Lysates were heated at 95ºC for 10min in reducing SDS-PAGE buffer and loaded 
into a polyacrylamide gel. Protein was then transferred to a polyvinylidene difluoride (PVDF) 
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membrane and blocked using 5% nonfat-dry milk. Primary antibody incubation was performed 
overnight at 4ºC using the following antibodies: mouse anti-calbindin-D28k (Swant, 1:1000), 
mouse anti-claudin-2 (Invitrogen, 1:500), and mouse anti-β-actin (Sigma-Aldrich, 1:1000). 
Horseradish peroxidase conjugated secondary antibodies were incubated at a concentration of 
1:5000 (GE Healthcare Bio-Sciences) and bands detected using chemiluminesence (Pierce). 
Quantitation of densitometry was achieved using ImageJ (NIH) and normalized to β-actin. 
3.3.4 Metabolic balance studies 
All metabolic balance studies were performed using mice between 14-18 weeks of age. 
Control (0.6% Ca2+, TD.97191) and calcium deficient (≤ 0.01% Ca2+, TD.95027) diet was 
purchased in powdered form (Envigo, Madison, WI) and prepared as a soft agar diet using 1% 
Difco Noble agar (BD Biosciences, San Jose, CA) in a ratio of 5:8 w/v diet to water. 
Mice were first acclimated in metabolic cages (MMC100, Hatteras Instruments, Cary, NC) 
for 48 hours with free access to food and water. Control diet was started at this time (Day -4). At 
Day -2, mice were returned to conventional housing for 2 days of recovery. At Day 0, mice were 
returned to metabolic cages for collection of urine and feces. Food weight, water weight, and urine 
volume were recorded each day, and mice were removed for approximately 10 minutes each day 
during collection of urine, feces, and cleaning of cages. At Day 5, a subset of mice was switched 
to the low calcium diet. At the completion of the study, serum was collected by cardiac 
exsanguination.  
3.3.5 Serum, urine, and fecal analysis 
Feces were collected in glass vials and calcium was extracted by wet ashing. Briefly, 2:1 
nitric: perchloric acid was added to each sample (3mL total) and heated at 95ºC until dissolved 
completely (~7 hours). Samples were serially diluted to a total volume of 400mL. 
Urine was collected in 2 separate tubes. One aliquot was acidified using 12N HCl to a total 
concentration of 0.3N HCl. All aliquots were then spun down at 5000 x g for 1 min at RT and 
stored in -80°C. 
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Serum, urine, and fecal calcium was measured by a colorimetric assay (Quantichrom, 
BioAssay Systems). Urine creatinine was measured by the Jaffe reaction using a commercial kit 
(Cayman Chemical). Serum creatinine was measured by the University of Texas Southwestern 
Medical Center (UTSW) O’Brien Center Kidney Physiology Core by capillary electrophoresis.  
Urine was also assayed for oxalate (EnzyChrom, BioAssay Systems), citrate (EnzyChrom, 
BioAssay Systems), magnesium (QuantiChrom, BioAssay Systems), and inorganic phosphorus 
(Pointe Scientific). 
3.3.6 Histological analysis 
Six month-old mice fed standard lab chow were anesthetized using ketamine and xylazine 
and cardiac perfusion fixation was performed using 4% paraformaldehyde (PFA) in PBS. Kidneys 
were post-fixed in 4% PFA for 4 hours at room temperature. 
Initial calcium staining was performed on paraffin-embedded sections that were 
deparaffinized and rehydrated. For von Kossa staining, sections were incubated in 5% aqueous 
silver nitrate for 1 hour under UV light, and 5% sodium thiosulfate for 1 min. For Alizarin Red S 
staining, tissues were placed in 2% Alizarin Red S, pH 4.3 for 1-3 min. 
 Immunofluorescence was performed on frozen sections. Fixed kidneys were 
cryoprotected in sucrose, embedded in OCT, and 5 µm sections were cut. Slides were first stained 
using the von Kossa technique. Antigen retrieval was then performed with 10 mM sodium citrate 
in a steamer for 6 min. Aldehyde quenching was accomplished by incubating in 0.3 M glycine in 
PBS, then slides were blocked for 1 hour in PBS with 5% normal goat serum, 1% BSA, and 0.3% 
Triton-X100. The primary antibodies used were: CLC-K (1:200, Alomone Labs), AQP1 (1:500, 
Abcam), AQP2 (1:500, a generous gift from Dr. Mark Knepper, NHLBI), MECA32 (1:100, 
Developmental Studies Hybridoma Bank, U. Iowa). Lipofuscin was quenched with 0.1% Sudan 
Black B in 70% ethanol for 15 min, before applying secondary antibodies (Alexa Fluor 488 and 
555-conjugated goat anti-rabbit and anti-mouse IgG, 1:1000, Thermo-Fisher). Confocal 
fluorescent images were captured along with brightfield images for von Kossa stain (Leica TCS 
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SPE microscope). Von Kossa images were pseudocolored, then overlayed onto the fluorescent 
images using ImageJ (NIH). 
3.3.7 Micro-CT analysis of kidneys 
Kidneys from 6 month-old mice were fixed and ethanol dehydrated and then scanned with 
a high-resolution micro-CT scanner (µCT40; Scanco Medical, Southeastern, PA) as previously 
described (Zelenchuk, Hedge et al. 2015). Data were acquired at 55 KeV and 6 µm cubic 
resolutions. Renal calcifications were assessed with a threshold of 220. 
3.3.8 Bone measurements 
Dual energy X-ray absorptiometry (DEXA,  Lunar PIXImus, GE Medical Systems) was 
used to measure bone mineral density in anesthetized mice (0.25x ketamine/xylazine cocktail) at 
4.7, 6, 8, and 10 weeks of age. Two different sites were determined by adjusting the region of 
interest: femur and lumbar vertebrae. Some animals were fed a pelleted calcium-deficient diet 
(TD.95027, Envigo) at 12 weeks of age for 4 weeks. During the low calcium diet, measurements 
were taken at 12, 13, 14, 15, and 16 weeks of age. Micro-CT analysis was performed on femurs 
from 10 week-old animals as described previously (Zelenchuk, Hedge et al. 2015). 
3.3.9 Transmission Electron Microscopy 
Renal papillae were dissected from fresh kidneys, fixed in 3% glutaraldehyde in 0.1 M 
cacodylate buffer, and post-fixed in 1% osmium tetroxide in 0.1 M cacodylate buffer for 1 hour. 
They were then dehydrated in ethanol and propylene oxide and embedded in EMBED 812 resin. 
Cross-sections were cut through the papilla block at 80 nm thickness and picked up on 250 mesh 
copper grids. Next, blocks were sectioned 10 µm deeper and the same sectioning process was 
repeated twice. These thin sections were then contrasted with 3% uranyl acetate aqueous and 
Sato’s lead stain. Grids were viewed at 100 kV in a JEOL JEM 1400 transmission electron 
microscope and images were captured as TIFF files with an AMT camera. 
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3.3.10 Micro-Fourier transform infrared spectroscopy 
Kidney sections (~5 µm) were mounted on low-E glass slides (Kevley Technologies, 
Chesterland, Ohio) for attenuated total internal reflection (ATR) imaging analysis. A serial section 
stained with Yasue silver replacement was employed as a control section. Prior to infrared 
analysis, the control was visually examined with an Olympus white light microscope (20x 
objective) to determine the areas of interest. Sections for ATR-FTIR imaging were not stained. 
ATR infrared images were collected with a PerkinElmer Spectrum Spotlight 400 infrared imaging 
microscope interfaced to a Perkin Elmer FTIR spectrometer, as described previously (Evan, 
Lingeman et al. 2003). Each image (400 x 400 µm area) had a spatial resolution of 1.56 µm/pixel 
and contained 65,746 infrared spectra collected at a spectral resolution of 8 wavenumbers. Each 
spectrum in the image is the average of 4 individual scans. The images were further processed 
used using Spectrum Image software (Perkin Elmer). 
3.3.11 Human DNA samples and genotyping 
The characteristics of samples are shown in Table 3-2. DNA samples of 6,246 kidney 
stone cases (study 1), 4,884 Kidney stone cases (study 2), and 158,772 non kidney-stone controls 
(study 2) were obtained from Biobank Japan (Hirata, Nagai et al. 2017, Nagai, Hirata et al. 2017). 
28,867 controls (study 1) were from three population-based cohorts, including the JPHC (Japan 
Public Health Center) -based prospective study (Tsugane and Sobue 2001), the J-MICC (Japan 
Multi-Institutional Collaborative Cohort) study (Hamajima and Group 2007), and ToMMo (Tohoku 
Medical Megabank Organization) (Matsuo, Oze et al. 2013, Kuriyama, Yaegashi et al. 2016). 
These samples were genotyped in previous studies by our collaborators (Kanai, Akiyama et al. 
2018, Tanikawa, Kamatani et al. 2018). Genomic DNA samples were extracted from peripheral 
blood leukocytes and normal tissues using a standard method. All participants provided written, 
informed consent and the ethical committees at each institute approved the project. All samples 




3.3.12 Imputation and Statistical analysis 
SNPs were excluded that met the following criteria: MAF <0.005; Hardy-Weinberg 
equilibrium P value < 1 x 10-6, Call rate =0 (study 1) or <0.01 (study 2). Imputation of the 
ungenotyped SNPs was conducted by MaCH (Scott, Mohlke et al. 2007) and minimac (Howie, 
Fuchsberger et al. 2012) using the data from the JPT/CHS/CHD subjects and using the 1000 
genome project phase 1 (release 16, March 2012) as a reference. We excluded SNPs with a large 
allele frequency difference between the reference panel and the genome wide association study 
(GWAS, >0.16) as described previously (Low, Takahashi et al. 2017). We also excluded SNPs 
with low imputation quality score (Rsq < 0.3) and insertion/deletion polymorphisms. Finally, we 
selected 12 SNPs within CLDN2 loci for association analysis. Association of these SNPs with 
kidney stone risk was assessed by logistic methods. Covariates used in each study are age, sex, 
and PC1 to PC10 (Price, Patterson et al. 2006). A meta-analysis of study 1 and study 2 was 
conducted by using METAL. Heterogeneity across the two stages was examined using the 
Cochrane’s Q test (Breslow and Day 1987). 
3.3.13 eQTL analysis 
Single-tissue cis-acting eQTL analysis was performed with FastQTL using Release V7 of 
the GTEx dataset in the GTEx Portal. Nominal p-values were generated for each CLDN2 gene 
variant by testing the alternative hypothesis that the slope of a linear regression model between 
genotype and claudin-2 expression, in pancreas samples from 220 individuals, deviates from 0. 
The normalized effect size of the eQTLs, defined as the slope of the linear regression, is 
computed in a normalized space where magnitude has no direct biological interpretation. 
3.3.14 Study approval 
All animal experiments were performed in accordance with NIH guidelines on the use of 
laboratory animals and were approved by the Institutional Animal Care and Use Committee at the 
University of Kansas Medical Center. For the GWAS, all human subjects provided written 
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informed consent. The study protocol conformed to the Declaration of Helsinki, and the study was 
approved by the ethical committee at the University of Tokyo. 
3.4 Results 
3.4.1 Deletion of Cldn2 in mice results in hypercalciuria and nephrocalcinosis 
Muto, et al. (2010) previously reported that claudin-2 knockout mice are hypercalciuric 
(Muto, Hata et al. 2010). Using an independent claudin-2 knockout mouse line (Pei, Solis et al. 
2016), I confirmed that urinary calcium excretion is increased (Table 3-3). Hypercalciuria is a 
major risk factor for nephrocalcinosis, the precipitation of calcium deposits within the kidney 
parenchyma and tubules, and the formation of kidney stones (Evan, Lingeman et al. 2014). I 
examined 6 month-old mice for evidence of calcium deposition within the kidney. Von Kossa 
staining, in which ionized silver precipitates with phosphate, showed numerous deposits localized 
to the renal papilla of Cldn2-/y mice (Figure 3-1A). In order to empirically determine the composition 
of these deposits, I used Alizarin Red S staining, which is specific for calcium and stains calcium 
phosphate or calcium carbonate at a pH of 4.2 (Proia and Brinn 1985). This revealed a similar 
pattern of calcium deposition as von Kossa staining (Figure 3-1B). While CaOx cannot be stained 
by Alizarin Red S at this pH, both CaOx and Alizarin Red S-calcium complexes should exhibit 
birefringence when examined under polarized light (Wolman 1975). Only Alizarin Red S positive 
areas showed birefringence by polarized light microscopy, suggesting the absence of CaOx 
deposits (Figure 3-1C). In order to verify these findings, I performed micro-FTIR and found that 
the composition of mineral in Cldn2-/y mice is composed primarily of calcium phosphate in the 
form of hydroxyapatite (Figure 3-1D). TEM revealed large circular mineral deposits with a “tree-
trunk”-like laminated appearance typical of hydroxyapatite (Figure 3-1E). These deposits 
appeared to be surrounded by a basement membrane, although no intact epithelium could be 
identified in the sections. I performed a time course to determine the onset of nephrocalcinosis 
as measured by X-ray micro-CT. There was scant mineral in wild type kidneys at all age groups 
examined. In contrast, none of the Cldn2-/y mice had papillary deposits at 4.5 months but all had 
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developed papillary deposition at 6 months and 1 year (Figures 3-1F & 3-1G). Cldn2-/- female 
mice also had extensive nephrocalcinosis at 1 year (data not shown). 
I used a combination of von Kossa and immunofluorescence staining to localize these 
deposits within the renal papilla in 6 month-old mice. No deposits were found within inner 
medullary collecting ducts or the vasa recta (Figures 3-2A & 3-2C). Occasionally, mineral was 
located within the lumen of aquaporin-1 (AQP1)-positive descending thin limbs or kidney-specific 
chloride channel (CLC-K) positive ascending thin limbs of the loops of Henle (Figures 3-2A and 
3-2B, arrows). However, the vast majority of deposits did not associate with any epithelial markers 
so I was unable to distinguish between intratubular deposits with denuded or damaged tubular 
epithelium and interstitial aggregates of mineral in the majority of deposits analyzed. To detect 
earlier deposits, I examined the papillae of 5 month-old Cldn2-/y mice by TEM. Calcium deposits 
in these mice were detected within lumina of intact tubules with type 4 cells of ascending thin 
limbs of the loops of Henle, identifiable by their extensive lateral interdigitations (Figure 3-2D), as 
well as type 3 cells of descending thin limbs of the loops of Henle, characterized by infrequent TJ 
strands (Pannabecker 2012) (Figure 3-2E). This indicates that deposits form in the loops of Henle 
throughout the papillary region. In support of this, the diameter of calcium deposits in 6 month-old 
Cldn2-/y mice on histological cross-sections and micro-CT reconstructions was approximately 20 
µm (Figure 3-3), similar to that reported for thin limbs of the loops of Henle (Pannabecker 2012).  
3.4.2 Hypercalciuria in Cldn2-/y mice is due to defective renal tubular calcium 
reabsorption  
FECa2+ was increased in Cldn2-/y mice compared with their wild type littermates (Table 3-
3). There was no significant difference in serum calcium levels (Table 3-3), and we previously 
showed that GFR is unchanged in Cldn2-/y mice (Pei, Solis et al. 2016). Hence, the filtered load 
of calcium is unchanged. This suggests that renal tubule calcium reabsorption is decreased in 
Cldn2-/y mice. As claudin-2 is predominantly expressed in the PT and is permeable to calcium 
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(Yu, Cheng et al. 2009), it is likely that Cldn2-/y mice are hypercalciuric due to impaired PT 
paracellular calcium transport. 
 Urine calcium excretion in Cldn2-/y mice might also be affected by changes in expression 
of calcium transporters in more distal segments of the kidney. We previously showed that 
expression of thick ascending limb (TAL) calcium transporters, such as claudin-16 and -19 and 
the electroneutral NKCC2 are not different between Cldn2-/y and wild type mice (Pei, Solis et al. 
2016). I found that protein expression of calbindin-D28k, a cytosolic calcium carrier protein known 
to be upregulated by 1,25(OH)2 vitamin D3 (Hoenderop, Nilius et al. 2005), is unchanged in Cldn2-
/y mice (Figure 3-4A-B). I also measured mRNA expression of claudin-14, a negative regulator of 
TAL paracellular calcium transport, and found no difference (Figure 3-4C). Similarly, I found no 
difference in mRNA expression of genes involved in active, transcellular calcium transport in the 
DCT and CNT, including TRPV5, calbindin-D28k, and the Na+-Ca2+ exchanger (NCX1) (Figure 3-
4C). Thus, changes in distal calcium transport proteins do not contribute to the hypercalciuria in 
Cldn2-/y mice, nor do they compensate for it. 
3.4.3 Concurrent intestinal hyperabsorption of calcium in Cldn2-/y mice 
If the hypercalciuria in Cldn2-/y mice is due to primary renal calcium wasting, we would 
expect them to be in negative calcium balance and hence to exhibit a compensatory increase in 
the calciotropic hormones, PTH and 1,25(OH)2 vitamin D3 (Hoenderop, Nilius et al. 2005). 
However, there were no significant differences in the levels of these hormones (Table 3-3). We 
would also expect Cldn2-/y mice to have calcium loss from bone, leading to reduced bone mineral 
density (BMD) and volume. To test this, I utilized DEXA analysis to measure BMD at 4.7, 6, 8, 
and 10 weeks of age. I found no detectable difference in either total or lumbar BMD in Cldn2-/y 
mice (Figures 3-5A & 3-5B). I analyzed femurs from 10 week-old mice using micro-CT and again 
found no difference in the density or quality of the bone between genotypes (Table 3-4). It is 
possible that Cldn2-/y mice could adequately compensate for calcium loss on a normal calcium 
diet. Thus, I switched a subset of animals to a low calcium diet at 12 weeks and measured BMD 
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weekly over the next 4 weeks. Again, there was no difference in BMD between wild type and 
Cldn2-/y mice (Figures 3-5A & 3-5B). Figure 3-5C shows representative micro-CT reconstructions 
of femurs from 10 week-old mice, which do not show any gross differences in cortical or trabecular 
bone in Cldn2-/y mice. Another group of mice was aged to one year and confirmed that Cldn2-/y 
mice BMD remained similar to wild type mice on a normal calcium diet (Figures 3-5D & 3-5E). 
 The finding that there was no change in the levels of PTH, 1,25(OH)2 vitamin D3 and BMD 
in Cldn2-/y mice despite marked hypercalciuria suggests that they may have concurrent intestinal 
hyperabsorption of calcium. Indeed, concurrent renal calcium wasting and intestinal 
hyperabsorption of calcium is typical of idiopathic hypercalciuria in patients with kidney stones 
and in hypercalciuric rats (Kim, Sessler et al. 1993, Moe 2006). Moreover, claudin-2 is known to 
be expressed in the intestinal tract. To test the hypothesis that there is also primary intestinal 
hyperabsorption of calcium in Cldn2-/y mice, I determined whether the hypercalciuria was 
attenuated by a reduction in dietary calcium content. I placed animals in metabolic cages on a 
control diet (0.6% Ca2+), and after 5 days switched half of them to a calcium-deficient (<0.01% 
Ca2+) diet (Figure 3-6A). I found that urinary calcium excretion in Cldn2-/y mice is highly sensitive 
to dietary calcium intake (Figure 3-6A). On the control diet, FECa2+ in Cldn2-/y mice was 
approximately five times higher than in wild type mice (0.69% vs. 0.14%, Figure 3-6B). In contrast, 
the FECa2+ of Cldn2-/y mice on the Ca2+-deficient diet was only twice that of wild type mice (0.22% 
vs. 0.11%) (Figure 3-6B). No differences in serum calcium were found between the groups (Figure 
3-6C). 
 These results suggest that hypercalciuria in Cldn2-/y mice is due to intestinal 
hyperabsorption of calcium, in addition to a primary renal calcium leak. To confirm this, I 
performed metabolic balance studies over a 3-day period on the control diet (0.6% Ca2+). As 
expected, renal calcium excretion was increased in Cldn2-/y mice (Figure 3-7A). Intestinal calcium 
absorption, determined from the difference between dietary calcium intake and fecal calcium 
content, was greater in Cldn2-/y mice than in wild type mice (Figure 3-7B). Net calcium balance 
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was slightly positive in Cldn2-/y mice and greater than in wild type mice (Figure 3-7C). I measured 
intestinal expression of TRPV6, calbindin-D9k, and the plasma membrane calcium ATPase 
(PMCA1) and found no difference between genotypes (Figure 3-8). 
3.4.4 Variants in the CLDN2 gene are associated with nephrolithiasis in the general 
population 
Because claudin-2 knockout in mice caused hypercalciuria and nephrocalcinosis, we 
hypothesized that genetic variants in CLDN2 might be associated with the risk of kidney stones 
in humans. To date, several GWAS of nephrolithiasis have been performed in the general 
population (Thorleifsson, Holm et al. 2009, Urabe, Tanikawa et al. 2012, Oddsson, Sulem et al. 
2015), but none of these studies have included the X chromosome in their analyses. To evaluate 
the role of CLDN2 in human kidney stones, we examined the association of 12 SNPs in the 
CLDN2 locus with disease risk. In this analysis, a total of 11,130 kidney stone cases and 187,639 
controls were analyzed (Tables 3-2 & 3-5). As a result, 9 SNPs showed significant association 
with disease risk with p-values of 0.0462-0.0055 (Table 3-6). Three of these SNPs, rs7057398, 
rs12008279, and rs5917027, were previously shown to be associated with chronic pancreatitis 
(Whitcomb, LaRusch et al. 2012). 
 My hypothesis predicts that causal variants for nephrolithiasis in CLDN2 should decrease 
claudin-2 tissue expression. I performed an analysis for cis-acting eQTL in CLDN2 using the 
dataset from the Genotype-Tissue Expression (GTEx) project. Seven of the SNPs associated with 
nephrolithiasis were genotyped in GTEx, and in all 7 cases, the nephrolithiasis risk allele was 
strongly associated with decreased claudin-2 expression in pancreatic tissue (Table 3-6). At this 
time, there are insufficient number of kidney cortex samples in GTEx to perform eQTL analysis of 
kidney expression. However, we know that CLDN2 has three alternative first exons and hence 
three alternative promoters. In the GTEx expression data, human kidney cortex and pancreas 
both exclusively express the same transcript (ENST00000540876.1) and therefore use the same 
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promoter. Thus, it is highly likely that transcriptional regulation by cis-acting eQTLs in these 2 
tissues is identical. 
 Interestingly, the alleles in CLDN2 that are associated with increased risk of pancreatitis 
(Whitcomb, LaRusch et al. 2012) are all associated with increased claudin-2 expression in the 
pancreas, and with decreased risk for nephrolithiasis (Figures 3-9 & 3-10). The strong reciprocal 
relationship between risk variants for these two diseases and tissue expression levels increases 
the likelihood that these represent true causal disease associations. 
3.5 Discussion 
PT calcium reabsorption is passive and follows sodium and water reabsorption. It was 
previously shown by Muto et al. (2010) that deletion of claudin-2, which is highly expressed in the 
PT, causes a reduction in TER and PNa in PTs ex vivo (Muto, Hata et al. 2010). My work adds to 
this by determining that Cldn2-/y mice have a large decrease in renal calcium reabsorption that 
cannot be explained by reduced expression of calcium transporters in the TAL or DCT / 
connecting tubule. Additionally, I found that Cldn2-/y mice remain hypercalciuric after 5 days on a 
calcium deficient diet. This suggests that, although these mice are able to conserve sodium similar 
to wild type animals on a normal and low sodium diet (Pei, Solis et al. 2016), they are unable to 
fully compensate for a proximal renal leak of calcium regardless of dietary calcium content. This 
evidence suggests that Cldn2-/y mice are deficient in PT calcium transport, implicating claudin-2 
as the mediator of paracellular calcium reabsorption in the PT. Ultimately, micropuncture 
experiments are needed to confirm a PT-specific calcium leak in Cldn2-/y mice. 
In addition, I found a slightly positive calcium balance and a pronounced effect of dietary 
calcium on urinary excretion in Cldn2-/y mice. These data suggest that, in addition to reduction in 
renal calcium reabsorption, altered calcium absorption or secretion in the gastrointestinal tract 
also occurs as a consequence of global claudin-2 deletion.  Similar to Cldn2-/y mice, recurrent 
kidney stone formers often exhibit both intestinal hyperabsorption of calcium and reduced renal 
calcium reabsorption (Worcester, Coe et al. 2008). Whether common mechanisms of idiopathic 
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hypercalciuria originate from intestinal hyperabsorption, reduced renal reabsorption, or primary 
defects in both tissues remains an open debate. However, given the calcium permeating 
properties of claudin-2, its low expression and highly restricted localization to intestinal crypts in 
adult mammals (Rahner, Mitic et al. 2001), and its regulation by 1,25(OH)2 vitamin D3 (Zhang, Wu 
et al. 2015), I find the hypothesis that loss of claudin-2 in the intestine directly causes increased 
paracellular calcium absorption unlikely. It should be noted that infection of Cldn2-/y mice with the 
enteropathogenic bacteria C. rodentium increases the permeability of the small intestine via the 
“leak pathway,” which allows the passage of solutes and larger molecules secondary to intestinal 
damage (Tsai, Zhang et al. 2017). However, loss of claudin-2 does not affect colonic histology 
and there is no difference in the baseline characteristics of fecal sodium and water excretion (Tsai, 
Zhang et al. 2017), suggesting that the “leak pathway” is not increased in healthy Cldn2-/y mice. 
As such, it is difficult to see how loss of claudin-2 would contribute to intestinal calcium 
permeability. Additionally, experiments by Tamura show that the small intestines of claudin-2 
knockout animals have reduced PNa (Tamura, Hayashi et al. 2011). Given the properties of 
claudin-2 as both a sodium and a calcium permeable pore, we would expect that calcium 
permeability is reduced as well. An intriguing possibility is that claudin-2 mediates intestinal losses 
of calcium. However, it is not clear what role, if any, dietary calcium plays in the regulation of 
intestinal calcium secretion so this may not explain the strong relationship between dietary 
calcium and urinary calcium excretion. 
The relevance of the present study is underlined by findings that the majority of recurrent 
kidney stone formers have hypercalciuria and reduced calcium reabsorption in the PT (Worcester, 
Coe et al. 2008).  Another important similarity between Cldn2-/y mice and recurrent kidney stone 
formers is the presence of calcium deposits in the renal papilla. My work suggests that claudin-2 
deletion and the subsequent increase in delivery of calcium to the loops of Henle leads to papillary 
nephrocalcinosis in mice. In humans, nephrocalcinosis is appreciable on CT scan in 
approximately one sixth of CaOx stone formers and three quarters of hydroxyapatite stone 
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formers (Bhojani, Paonessa et al. 2015). It is well established that Randall’s plaques are a 
precursor to the most common stones, composed of CaOx, as residual plaque is found in 
approximately one third of intact stones (Letavernier, Vandermeersch et al. 2015). On endoscopic 
examination, 74% of stone formers have Randall’s plaques identified on the papillary epithelium 
surface, compared with 43% of non-stone forming patients (Low and Stoller 1997). Expressed as 
a percentage, increased coverage of plaque on the papillary epithelium is associated with CaOx 
stones as well as high urine calcium and low urine volume (Kuo, Lingeman et al. 2003). 
Unfortunately, no animal models have yet been identified which recapitulate the deposition of 
calcium phosphate within the basement membranes of the loops of Henle (Wu 2015). One 
potential reason for the failure to reproduce Randall’s plaques in mice is the comparative 
differences between mice and humans in medullary architecture (Wu 2015). Whereas the 
papillary epithelium of the loops of Henle is surrounded by expansive interstitial connective tissue 
in humans, the majority of loops of Henle in mice have sparse interstitial tissue and are closely 
apposed with one another and other papillary tubules. 
A form of nephrocalcinosis characterized by intratubular plugs of calcium is even more 
common than Randall’s plaques, found in the papillae of 92% of cancer patients without a history 
of kidney stone disease (Huguet, Le Dudal et al. 2017). The presence of medullary plugging is 
highly associated with Randall’s plaques (Verrier, Bazin et al. 2016). Intratubular plugs are 
composed of calcium phosphate and located within AQP1 negative loops of Henle (Huguet, Le 
Dudal et al. 2017), consistent with both the lowermost portions of descending thin limbs and the 
ascending thin limbs (Wei, Rosen et al. 2015). Observations that intratubular plugs correlate with 
the presence of Randall’s plaques have led to a newly proposed model of nephrocalcinosis and 
stone formation in humans, in which medullary plugging precedes plaque formation and 
subsequent stone growth (Hsi, Ramaswamy et al. 2017). Indeed, present evidence suggests that 
the severity and density of upstream calcium phosphate medullary plugging can predict Randall’s 
plaque deposition (Hsi, Ramaswamy et al. 2017, Sherer, Chen et al. 2018). The nephrocalcinosis 
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I have identified in Cldn2-/y mice is remarkably similar to the intratubular plugs described in kidney 
stone patients, despite the lack of Randall’s plaque-like structures. 
In addition to Randall’s plaque-associated CaOx stone formers, a significant proportion of 
stone formers develop calcium phosphate stones (Evan, Lingeman et al. 2014). This stone type 
is associated with intratubular plugs of calcium phosphate, rather than Randall’s plaques. 
However, this tubule plugging is localized to the inner medullary collecting ducts in these patients 
(Evan, Lingeman et al. 2014).  Clearly, Cldn2-/y mice share features of both types of stone formers, 
as they form nephrocalcinosis that is localized to the loops of Henle similar to Randall’s plaques 
but is located within tubular lumina rather than the interstitium, mimicking calcification found in 
hydroxyapatite stone formers (Evan, Lingeman et al. 2014) or that which is common in the general 
population but has not been definitively linked to kidney stone disease. 
Given the significant differences between nephrocalcinosis in stone forming humans and 
Cldn2-/y mice, it is useful to revisit previous mouse models of kidney stone disease. A number of 
mouse models have been described that share elements of human kidney stone disease. For 
instance, models involving distal calcium transporters such as Trpv5-/- (Hoenderop, van Leeuwen 
et al. 2003, Renkema, Velic et al. 2009) and Cldn16-/- (Will, Breiderhoff et al. 2010) mice have 
hypercalciuria but lack papillary nephrocalcinosis or nephrolithiasis under normal conditions. In 
each case, it has been presumed that the lack of nephrocalcinosis is due to compensatory 
adaptations by the kidney. Perhaps due to the fact that many adaptations occur in the distal 
tubule, such as acidification of the urine by the H+-ATPase proton pump or reduced water 
transport via AQP2 (Renkema, Velic et al. 2009), Cldn2-/y mice are unable to prevent 
nephrocalcinosis within the more proximal loops of Henle.  It should be noted that mild calcification 
was shown in the medullae of transgenic claudin-16 knockdown mice (Hou, Shan et al. 2007) and 
patients with loss-of-function mutations in claudins-16 and -19, causing FHHNC, develop 
medullary calcifications early in life (Konrad, Hou et al. 2008). This does suggest a role for distal 
calcium transport in renal calcification. However, FHHNC pathology is severe and distinct from 
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idiopathic kidney stone formers, characterized by immature glomeruli, fibrosis, 
glomerulosclerosis, and declining renal function (Kuwertz-Broking, Frund et al. 2001). 
Additionally, several mouse models of papillary nephrocalcinosis have been described in 
which proteins involved in the inhibition of crystal formation are ablated, such as osteopontin 
(encoded by gene Opn) and Tamm-Horsfall protein (encoded by gene Thp) (Mo, Liaw et al. 2007). 
Only about half of Thp-/- mice were reported to have nephrocalcinosis present at 6 months of age 
(Liu, Mo et al. 2010), and nephrocalcinosis was reported to be even less frequent in Opn-/- mice 
(Mo, Liaw et al. 2007). Hypercalciuria is not present in either mouse model (Mo, Liaw et al. 2007). 
Dysfunctional phosphate transport in the PT, as occurs in mice with deletion of the type II sodium 
phosphate cotransporter (Npt2a) or sodium hydrogen exchange regulator factor-1 (NHERF1), 
also results in papillary nephrocalcinosis. Npt2a-/- mice, for instance, have renal phosphate 
wasting, hypophosphatemia, and hypercalcemia in addition to hypercalciuria, and develop 
nephrocalcinosis more severely within cortex than medulla (Khan and Glenton 2008). Similarly, 
NHERF1 loss causes reduction of Npt2a in the PT and leads to phosphate wasting, 
hypophosphatemia, hypercalciuria, and nephrocalcinosis (Weinman, Mohanlal et al. 2006). 
Contrast all of these mouse models with Cldn2-/y mice, in which urinary calcium excretion is high, 
serum and urinary phosphate are normal (Muto, Hata et al. 2010, Schnermann, Huang et al. 
2013), and 100% of mice at 6 months and 1 year of age had clearly appreciable papillary 
deposition of mineral on micro-CT reconstructions. I purport that these characteristics make 
Cldn2-/y mice a more physiologically relevant model of human idiopathic kidney stone disease 
than has previously been described (Wu 2015). An important advance I have made in studying 
kidney stone disease is that previous models of papillary nephrocalcinosis relied solely on 
histological analyses to detect calcium deposition in kidneys, whereas I utilized micro-CT with a 
high sensitivity for detecting nephrocalcinosis in intact kidneys. This technique should aid future 
studies focused on nephrocalcinosis and kidney stone disease. 
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The striking findings of hypercalciuria and papillary nephrocalcinosis in Cldn2-/y mice led 
us to test the hypothesis that polymorphisms in the CLDN2 locus associate with kidney stone 
disease. Our analysis identified 9 SNPs that are associated with nephrolithiasis, many of which 
are incredibly common in the general population. Subsequent eQTL analysis revealed that 7 of 
the SNPs identified share a strong association with reduced claudin-2 expression in human 
pancreatic tissue. Unexpectedly, the non-risk alleles of several of these SNPs have been 
identified previously with regards to alcohol-related pancreatitis and increased pancreatic claudin-
2 expression. We hypothesize that, in addition to reducing claudin-2 expression in the pancreas, 
these SNPs result in lowered claudin-2 expression in the kidney. Our future studies will aim at 
analyzing genotype-renal gene expression association as has been described recently (Ko, Yi et 
al. 2017). 
In conclusion, the evidence I present suggests that paracellular calcium transport in the 
proximal nephron is mediated at least in part by claudin-2, and deletion of claudin-2 leads to 
intratubular deposition of calcium in the loops of Henle. This pattern of deposition is similar to 
nephrocalcinosis in human subjects, and mounting evidence suggests that a direct relationship 
exists between the abundance and density of these deposits, Randall’s plaques, and idiopathic 
kidney stone disease. The relevance of these findings is highlighted by our findings that common 
SNPs in the CLDN2 locus associate with kidney stone disease. Importantly, these SNPs are 
significantly associated with reduced tissue expression of claudin-2. Conditional knockout studies 
are needed to determine the absolute contribution of renal claudin-2 expression to hypercalciuria 
in Cldn2-/y mice. Future studies will focus on potential pharmacologic strategies to increase renal 
claudin-2 expression, as this may be a useful strategy for the preventative treatment of recurrent 
kidney stone formation.  
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Table 3-3. Serum and urinary parameters of mice on standard lab chow 
Parameter   Wild type      Cldn2-/y   
  Mean SEM n Mean SEM n P value  Serum 
Calcium (mg/dL) 10.24 0.17 9 10.74 0.43 8 0.27 
1,25-dihydroxyvitamin D (pmol/L) 193 13 8 201 21 8 0.74 
PTH (pg/mL) 696 158 11 699 134 10 0.99 
Urine              
FECa (%) 0.11 0.01 8 0.20 0.01 7 0.0001 
Phosphorus/Cr (mg/mg) 7.73 1.64 8 6.65 1.76 5 0.67 
Oxalate/Cr (mg/mg) 0.09 0.01 5 0.12 0.01 4 0.22 
Citrate/Cr (mg/mg) 6.79 0.58 8 7.11 0.95 5 0.76 
Mg/Cr (mg/mg) 3.57 0.20 8 3.11 0.25 5 0.18 
 








*P<0.05 vs. wild type using Student’s t-test 
Index: BS = bone surface; BS/BV = bone-surface/total-bone volume (1/mm); BV/TV = bone-
volume/total-volume (%); Tb.N = trabecular number; Tb.Th = trabecular thickness; Tb.Sp = 
trabecular spacing; Connectivity = number of connected structures calculated by the Euler 
characteristic; SMI = structural modeling index; Anisotropy = anisotropic index of 
longitudinal/traverse tensile compressive force resistance; MOI = moment of inertia; Ct.Th = 
cortical thickness; TVδ = total tissue-volume excluding marrow-volume;  BV/TVδ =bone 
volume/TVδ (%); MVρ = (TVα-BV) = marrow-volume of defined region of interest (ROI) of 
central diaphysis (mm3) where TVα is the total tissue volume including marrow volume and TVδ 
(mm3); BA = bone area; TA = total area; Periosteal circumference = bone-area; Endosteal 




 Wild type Cldn2-/y 
 
  








BS/BV 97.1 ± 2.4 92.6 ± 6.2 
BV/TV trabecular 0.0426 ± 0.0049 0.0507 ± 0.0083 
BV/TV cortical 0.992 ± 0.001 0.993 ± 0.000 
Tb.N (1/mm) 3.65 ± 0.41 4.01 ± 0.06 
Tb.Th (mm) 0.0305 ± 0.0025 0.0332 ± 0.0021 
Tb.Sp (mm) 0.290 ± 0.043 0.247 ± 0.005 
Connectivity (1/mm3) 47.8 ± 13.7 74.6 ± 12.9 
SMI (1) 3.08 ± 0.09 2.82 ± 0.12 
Anisotropy (1) 1.55 ± 0.05 1.60 ± 0.08 
MOI (mm4) 0.532 ± 0.024 0.613 ± 0.021* 
Ct.Th (mm) 0.154 ± 0.008 0.149 ± 0.011 
Cortical bone MOI (mm4) 0.337 ± 0.035 0.378 ± 0.058 
BV (mm3) 1.33 ± 0.09 1.51 ± 0.12 
TVδ (mm3) 1.32 ± 0.09 1.50 ± 0.13 
BV/TVδ 0.988 ± 0.002 0.990 ± 0.001 
TVα (mm3) 2.93 ± 0.15 3.36 ± 0.21 
BV/TVα 0.451 ± 0.008 0.447 ± 0.010 
Ct.Th (mm) 0.184 ± 0.009 0.188 ± 0.010 
BS/BV 11.5 ± 0.5 11.2 ± 0.5 
BS (mm2) 15.1 ± 0.4 16.8 ± 0.6 
MVρ=TVα-BV (mm3) 1.60 ± 0.06 1.86 ± 0.09* 
BA (mm2) 0.758 ± 0.050 0.798 ± 0.068 
TA (mm2) 1.68 ± 0.08 1.78 ± 0.11 
BA/TA 0.451 ± 0.008 0.447 ± 0.010 
Periosteal circ. (mm) 4.58 ± 0.11 4.72 ± 0.15 
Endosteal circ (mm) 3.39 ± 0.06 3.51 ± 0.09 
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allele MAF METAL GTEx 
    OR P-value Expression ratio P-value 
rs7057398 T C 0.4848 1.029 0.0152 0.619 1.7E-15 
rs55662019 A T 0.1099 0.917 0.0113 1.139 0.059 
rs12837024 C T 0.231 1.0303 0.0200 0.638 2.8E-12 
rs73247968 C A 0.1465 1.035 0.0462 0.644 1.2E-08 
rs12008279 G A 0.3698 0.915 0.0085 1.162 5.7E-03 
rs5917027 C T 0.2477 0.925 0.0055 1.297 2.4E-06 
rs6523906 A G 0.3746 0.925 0.0055 1.234 1.0E-04 
rs6622121 T C 0.3828 0.926 0.0057   
rs147829672 C A 0.014 0.927 0.0080   
 
METAL, association of variants with nephrolithiasis by meta-analysis of two independent GWAS 
GTEx, association of variants with claudin-2 tissue expression in pancreas by eQTL analysis 
MAF, minor allele frequency (1000 genome project) 
OR, odds ratio for nephrolithiasis with minor allele as the reference allele. When major allele is 
associated with disease risk, OR is >1. 









Figure 3-2. Nephrocalcinosis occurs within the loops of Henle of Cldn2-/y mice. 
Confocal microscopy of papillary sections from Cldn2-/y mice shows von Kossa staining of 
deposits (pseudo-colored white) co-labeled with the following tubule markers: (A) Inner medullary 
collecting duct (AQP2) and thin descending limbs (AQP1), (B) thin descending limbs (AQP1) and 
thin ascending limbs (CLC-K), and (C) Inner medullary collecting ducts (AQP2) and vasa recta 
(MECA-32). Association of calcium deposits with tubule markers is infrequent, but instances of 
colocalization with AQP1 or CLC-K positive thin limbs are occasionally seen (arrows in A and B). 
Scale bars = 50 µm. Electron microscopy of papillae from 5 month-old Cldn2-/y mice shows small 
mineral deposits within (D) type 4 thin descending limb cells with frequent tight junctions 




Figur e 3 -3. R epr esen tative cross -secti on i mag es use d fo r q uantit atio n of c alcium  de posit di am eter .  




Figure 3-4. Renal expression of calcium transporters is not different in Cldn2-/y mice. 
Quantitation of calcium transporters in wild type (WT) and Cldn2-/y (KO) mice. (A) Western 
blotting for calbindinD-28k and claudin-2 and (B) quantitation of calbindin-D28k protein 
expression. (C) Quantitative PCR measurements of renal calcium transporters shows no 
difference in mRNA expression (n=4 per group, with the exception of TRPV5 n=5). Bars are 






Figure 3-5. Bone mineral metabolism is not changed in Cldn2-/y mice. 
Bone analysis on wild type (blue) and Cldn2-/y (red) animals on a standard chow diet. (A) Total 
and (B) lumbar bone mineral density (BMD) was measured using DEXA for at 4.7, 6, 8, and 10 
weeks. A group of these animals was started on a low Ca2+ diet for 4 weeks and BMD measured 
weekly. (C) Representative micro-CT reconstructions of femurs showing normal cortical and 
trabecular bone in Cldn2-/y mice. (D) Total BMD and (E) total bone mineral content were measured 






Figure 3-6. Hypercalciuria in Cldn2-/y mice is sensitive to dietary calcium intake. 
(A) Metabolic cage experiments show 24 hour urine calcium (Ca2+) excretion on control diet until 
day 5, after which half of the animals are switched to a Ca2+-deficient diet (<0.01% Ca). At Day 
10, the experiment was terminated and serum was collected. (B) Fractional excretion of Ca2+ 
(FECa) at day 10. Data were analyzed by two-way ANOVA with Bonferroni’s correction for 
multiple comparisons; **P<0.01; ****P<0.0001. (C) Serum Ca2+ at day 10. There were no 






Figure 3-7. Cldn2-/y mice have a positive calcium balance. 
Over the course of 3 days, urine and feces were collected for measurement of calcium (Ca2+) 
balance. (A) Total 3 day urinary Ca2+ excretion. (B) Intestinal Ca2+ absorption, determined as the 
difference between dietary Ca2+ intake and fecal Ca2+content and expressed as a percentage of 
dietary intake. (C) Net Ca2+ balance (intestinal absorption minus urinary excretion) is significantly 





Figure 3-8. Expression of intestinal calcium transporters in Cldn2-/y mice is not different 
from wild type. 
Quantitative-RT PCR of duodenal tissue was used to measure expression of calcium transport 
proteins in the intestine in wild type (WT) and Cldn2-/y (KO) mice. Fold change values were 
calculated relative to GAPDH expression, and then data was normalized to 100% for wild type 






Figure 3-9. Linear regression analysis of pancreatic claudin-2 expression and disease 
risk. 
Odd ratios of SNPs reported by Whitcomb et al. (2012) regarding alcohol-related pancreatitis and 
the present study of kidney stone disease are shown plotted against pancreatic claudin-2 
(CLDN2) expression data (obtained from GTEx Portal). Linear regression analysis shows CLDN2 
expression is highly and reciprocally correlated with disease risk for chronic pancreatitis 









Chapter 4: Conclusion 
 
4.1 Summary of findings 
Defective PT calcium reabsorption is implicated in the pathogenesis of human kidney 
stone disease, and the majority of this transport is likely to be paracellular. Given that paracellular 
permeability is in large part determined by the claudin family of proteins, in chapter 2 I sought to 
establish the expression pattern of the three major claudin isoforms in the PT, claudin-2, claudin-
3, and claudin-10a. Claudin-2 and claudin-10 are expressed throughout the length of the PT, but 
claudin-3 is restricted to the PST. I found that, while claudin-2 is expressed in thin descending 
limbs of long loop nephrons, claudin-3 is expressed in a distinct population of descending thin 
limbs. I developed stable cell lines with inducible expression of claudin-2 and either claudin-3 or 
claudin-10a in order to study the paracellular transport properties of these isoforms, in vitro. I 
found that, of the major PT claudin isoforms, only claudin-2 increases calcium flux in vitro. 
In chapter 3, I investigated the mechanisms for hypercalciuria and nephrocalcinosis in 
Cldn2-/y mice, a novel mouse model for human kidney stone disease. I confirmed that these 
animals have an increase in the FECa2+, which is a risk factor for nephrocalcinosis and kidney 
stone disease in humans. I next analyzed kidneys from these mice for the presence of calcium 
deposits within the renal parenchyma, and identified intratubular calcium phosphate deposits, in 
the form of hydroxyapatite, within loops of Henle of the renal papilla. Using expression and 
metabolic balance studies, my work shows that Cldn2-/y mice are hypercalciuric due to both 
defective renal calcium reabsorption and intestinal hyperabsorption of calcium. Given the striking 
nephrocalcinosis phenotype in Cldn2-/y mice, we tested the hypothesis that CLDN2 
polymorphisms may contribute to kidney stone risk in humans. We identified 9 SNPs in the CLDN2 
locus that had a significant association with kidney stone disease. Utilizing genotype-tissue 
expression analysis of human subjects (GTEx Portal), I show that these SNPs strongly associate 
with reduced claudin-2 expression in human pancreatic tissue. Both kidney and pancreas express 
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the same transcript of claudin-2, suggesting similar transcriptional regulation in these tissues. The 
combined results suggest that these CLDN2 polymorphisms lead to decreased renal claudin-2 
expression and a subsequent increase in nephrolithiasis risk. 
4.2 Limitations 
A caveat of my claudin overexpression studies is that, while all of our present knowledge 
points to claudin-10a as the exclusive isoform of claudin-10 expressed in the PT, isolated PSTs 
have not been analyzed in any studies that distinguish between claudin-10 isoforms (Gunzel, 
Stuiver et al. 2009, Lee, Chou et al. 2015). Due to the fact that our claudin-10 antibody is directed 
against the C-terminus of the protein, I am unable to distinguish between isoforms in our 
immunolabeling studies. While claudin-10a is an anion-selective isoform, claudin-10b exhibits 
cation selectivity (Van Itallie, Rogan et al. 2006). Thus, I cannot completely eliminate the 
possibility that claudin-10b is expressed in PST and contributes to PT calcium reabsorption. As 
discussed in Chapter 2, I believe that this is unlikely given the scarcity of claudin-10b expression, 
as detected by in situ hybridization, in the outer stripe of the outer medulla (Van Itallie, Rogan et 
al. 2006). 
While our dual-claudin induction cell model can mitigate concerns in the variability in 
endogenous claudin expression between clonal cell populations, I cannot completely rule out an 
effect of endogenous claudin interactions on the calcium flux and electrophysiological studies. 
This is particularly true of claudin-3, which is one of the relatively abundant endogenous claudin 
isoforms expressed in MDCK I cells (Amasheh, Meiri et al. 2002, Yu, Cheng et al. 2009). I have 
taken care to select a clone with low endogenous claudin-3 expression for the claudin-3 studies, 
but a member of the lab has developed a TALEN-based knockout strategy for canine claudin-3 
and successfully generated knockout cells for future studies in the method described in his 
previous work (Tokuda and Furuse 2015). Ultimately, a powerful tool for in vitro studies would be 
a renal epithelial cell model that lacks all endogenous claudin protein expression. Such a model 
may be achievable using CRISPR/Cas9 nuclease technology, which has been developed as a 
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tool for multiplex genomic editing and is capable of targeting multiple genes at once (Cong, Ran 
et al. 2013). 
Given that the Cldn2 gene is on the X chromosome, the majority of my animal studies 
were limited to male mice in order to generate wild type and knockout littermates. As such, I 
cannot exclude the possibility that my metabolic data is sex-specific. It should be noted that I did 
quantitate nephrocalcinosis in female Cldn2 knockout animals and found that they develop 
nephrocalcinosis in a similar pattern and degree as their male counterparts. 
Another important caveat is that our Cldn2-/y mice have a global deletion of Cldn2. Given 
the complexity of calcium homeostasis, in vivo, it is possible that loss of claudin-2 leads to 
hypercalciuria and nephrocalcinosis due to loss of claudin-2 in extra-renal, extra-intestinal tissues. 
Indeed, claudin-2 is expressed in a number of other tissues including the choroid plexus and 
pancreas (Rahner, Mitic et al. 2001).  As shown in chapter 2, claudin-2 is also expressed in the 
kidney outside of the PT, in the thin descending limbs of long loop nephrons. Our lab is currently 
in the process of generating conditional (Cre-Lox) Cldn2 knockout mice, which will allow us to 
delete Cldn2 specifically within the PT. This model will ultimately be needed to determine the 
contribution of renal and intestinal claudin-2 to hypercalciuria and nephrocalcinosis in mice. 
I was surprised to find intestinal hyperabsorption of calcium in Cldn2-/y mice, given the 
limited expression of claudin-2 to intestinal crypts and the decreased intestinal PNa previously 
described in claudin-2 knockout animals (Holmes, Van Itallie et al. 2006, Tamura, Hayashi et al. 
2011). The expected result was the opposite; that loss of calcium-permeable claudin-2 would 
decrease intestinal calcium permeability and thus calcium absorption. Studies are currently being 
completed to measure intestinal calcium transport both in vivo, using oral gavage of radiotracer 
calcium, and ex vivo, by measurement of unidirectional flux of calcium in ileal tissue. These 




4.3 Significance and future directions 
4.3.1 The dual-claudin induction model 
Using the dual-claudin induction system, I found no effect of claudin-3 on TER, PNa, or PCl 
in MDCK I cells. This begs the question of what role claudin-3 plays in the PT in vivo. Of particular 
interest to us is the role of claudin-3 in the passive movement of urea and water across the TJ, 
given its localization within the PST and thin descending limbs of, presumably, short loop 
nephrons. I speculate that claudin-3 may modulate the ratio of urea permeability to PNa, in vitro, 
thereby increasing urea recycling and increasing the efficiency of the countercurrent multiplication 
mechanism for urinary concentration (Jamison 1987). Future studies may use this system to 
measure the flux of radiotracer urea, utilizing our dual-claudin induction system. 
My findings show that claudin-2 and claudin-10a co-expression leads to a reduction in 
permselectivity in MDCK I cells. The physiological relevance of expression of both cation- and 
anion-selective claudin isoforms in the PT is not clear. One possibility is that co-expression of 
claudin-2 and claudin-10a is synergistic in the facilitation of the isosmotic movement of sodium, 
calcium, chloride, and water. In the absence of claudin-2, PT chloride reabsorption may be 
blunted by the more positive lumen potential (normally dissipated by movement of cations across 
the TJ). Indeed, isolated perfused PTs from claudin-2 knockout mice have reduced chloride 
reabsorption, in addition to reduced sodium and water reabsorption (Muto, Hata et al. 2010). 
These mice also have a large increase in the fractional excretion of chloride in response to 
hypertonic saline injection (Muto, Hata et al. 2010). I speculate that genetic deletion of claudin-
10a would lead to similar findings: decreased PT sodium, calcium, and water reabsorption, in 
addition to defective chloride reabsorption. This relationship may be further explored using our 
dual-claudin induction model. It would be interesting to know if co-expression of claudin-2 and 
claudin-10a could increase the movement of both sodium and chloride along a concentration 
gradient, in spite of the overall reduction in PNa and PCl. Experiments could be performed to 
measure the flux of sodium and chloride across the cells in the presence of a gradient, taking care 
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to minimize the effect of unstirred layers (Winne 1973). I speculate that there would be a greater 
sodium and chloride flux than expected, given the measured PNa and PCl. This could be further 
explored utilizing our cysteine mutant cell model in order to block the claudin-2 pore and measure 
the difference in sodium flux. I would expect that the reduction in sodium flux following MTSEA 
addition would be much greater, as a percentage, in cells that express both claudin-2 S68C and 
claudin-10a compared with claudin-2 S68C alone. 
Endogenous claudin expression can vary between clonal cell populations and complicate 
the interpretation of claudin overexpression in vitro (Gunzel and Yu 2013). Our dual-claudin 
induction system partially circumvents this problem for co-expression studies and provides a 
novel tool in the field of claudin biology. In the future, this system may be used for the rigorous 
evaluation of claudin mutations by allowing their direct comparison with wild type isoforms at equal 
expression levels and within a single clonal cell population. This system will eliminate many of the 
concerns of such studies to date. 
4.3.2 Claudin-2 and the treatment of kidney stones 
Of the major PT claudins, only claudin-2 increased calcium permeability in vitro. Thus, my 
work strengthens the hypothesis that claudin-2 is the protein mediator of paracellular calcium 
transport in the PT. In my analysis of Cldn2-/y mice, I described findings of nephrocalcinosis, 
increased calcium balance, and increased FECa2+ upon calcium restriction. This suggests a role 
for claudin-2 in kidney stone formation. Following up on these findings, we subsequently identified 
significant genetic associations between CLDN2 polymorphisms and human kidney stone 
disease. The knowledge gained from this work may help identify common mechanisms for stone 
formation in the general population and pave the way for improved treatments for kidney stone 
disease. 
Recent findings linking the severity of papillary nephrocalcinosis and kidney stone disease 
in patients make my findings in Cldn2-/y mice particularly exciting (Verrier, Bazin et al. 2016, Hsi, 
Ramaswamy et al. 2017, Huguet, Le Dudal et al. 2017, Sherer, Chen et al. 2018). There are 
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currently no mouse models of nephrocalcinosis that form hydroxyapatite mineral around the 
basement membranes of the thin descending limbs, similar to Randall’s plaques (Wu 2015). 
Cldn2-/y mice do not form hydroxyapatite mineral in this fashion, either. However, these mice 
develop intratubular hydroxyapatite deposits within the thin limbs.  Similar intratubular mineral 
deposition has been identified as a risk factor for kidney stone formation (Okada, Hamamoto et 
al. 2018). I speculate that Cldn2-/y mice provide the best model to date for the study of 
nephrocalcinosis secondary to hypercalciuria. Using this model and our micro-CT method for the 
quantification of nephrocalcinosis will allow the testing of novel compounds that may reduce 
deposit formation in patients with defective PT calcium reabsorption. 
Cldn2-/y mice as a model may also improve our understanding of the pathogenesis of 
nephrocalcinosis and kidney stone disease. For instance, we are unsure what contribution, if any, 
calcium reabsorption in the TAL and subsequent countercurrent papillary blood flow through the 
renal vasculature (“vas washdown”) has on nephrocalcinosis (Coe, Worcester et al. 2016). Using 
transgenic claudin-16 knockdown mice, a model with defective TAL calcium reabsorption (Hou, 
Shan et al. 2007), we can test the contribution of “vas washdown” to the formation of 
nephrocalcinosis in Cldn2-/y mice. I would expect that, in the event of a major contribution to 
nephrocalcinosis by “vas washdown,” knockdown of claudin-16 should reduce or prevent 
nephrocalcinosis in Cldn2-/y mice. In addition, given that the majority of patients with idiopathic 
hypercalciuria and kidney stone disease develop CaOx stones, we may be able to induce 
hyperoxaluria in Cldn2-/y mice and cause the formation of CaOx crystals on the surface of the 
papilla and/or Randall’s plaques. If we are able to induce CaOx stones in Cldn2-/y, the model can 
be further used to improve our current understanding of kidney stone pathogenesis and develop 
novel treatments for kidney stones. 
In kidney stone formers with idiopathic hypercalciuria, reduction of urine calcium is 
important and necessary for prevention of stone recurrence (Borghi, Schianchi et al. 2002). While 
initially it was thought that restriction of dietary calcium would reduce stone recurrence, calcium 
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can form a complex with oxalate and prevent its absorption in the gastrointestinal tract (Borghi, 
Schianchi et al. 2002). As a result, calcium restriction increases oxalate absorption and will 
potentially exacerbate CaOx kidney stone disease. Thus, hypercalciuric stone formers must often 
be treated pharmacologically. A common treatment in such patients are thiazide diuretics, which 
reduce urine calcium in part by stimulating calcium reabsorption within the PT (Nijenhuis, Vallon 
et al. 2005, Worcester and Coe 2010). Unfortunately, a number of patients are unable to use 
these diuretics due to off-target side effects. Identification of claudin-2 as the protein mediator of 
PT calcium reabsorption will provide a novel drug target for the treatment of idiopathic 
hypercalciuria. Given that decreased claudin-2 expression in human tissues is associated with 
CLDN2 risk variants, I suspect that increasing claudin-2 expression in the kidney 
pharmacologically would protect from kidney stone recurrence. Thus, exploring the regulatory 
pathways for claudin-2 expression in the PT will be an important future direction for our work. 
A number of studies have identified cell signaling pathways that regulate claudin-2 
expression in vitro. For instance, claudin-2 is regulated by numerous cytokines and growth factors 
such as Interleukin-6, Tumor Necrosis Factor-α and Epidermal Growth Factor through the 
MEK/ERK pathway (Dhawan, Ahmad et al. 2011, Suzuki, Yoshinaga et al. 2011, Amoozadeh, 
Dan et al. 2015). In addition, activation of the Protein Kinase C- β pathway in response to 
hyperosmolarity has been shown to downregulate claudin-2 expression (Ikari, Fujii et al. 2015). 
Finally, intestine specific deletion of Hepatocyte Nuclear Factor-4α leads to upregulation of 
intestinal claudin-2 (Cattin, Le Beyec et al. 2009). Identification of the pathways involved in renal 
claudin-2 expression in vivo could allow for the development of novel drugs to treat hypercalciuria 
in kidney stone formers. 
Finally, in the emerging age of precision medicine, the identification of genetic 
associations may begin to help physicians make personalized decisions in disease management. 
For instance, the identification of kidney stone patients with common CLDN2 risk variants may 
help to identify a subpopulation of stone formers whose response to treatments such as thiazide 
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diuretics differs from patients without these risk variants. The knowledge gained from my work 
may ultimately have a large impact on our understanding of the pathogenesis of nephrocalcinosis 
and kidney stone disease. 
4.4 Concluding statement 
This dissertation has explored the role of claudin-2 as the most likely protein mediator of 
paracellular calcium transport in the PT. Given the importance of PT calcium reabsorption in the 
pathogenesis of idiopathic hypercalciuria and kidney stone formation (Sutton and Walker 1980, 
Sakhaee, Nicar et al. 1985, Worcester, Coe et al. 2008), we were able to establish a link between 
claudin-2 and the development of hypercalciuria, nephrocalcinosis, and nephrolithiasis using 
human genome association analysis, human tissue expression analysis, and a mouse model with 
global deletion of Cldn2. My hope is that this work will lead to a better understanding of the 
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